PPP2CB

UniProt ID: P62714
Organism: Homo sapiens
Review Status: IN PROGRESS
📝 Provide Detailed Feedback

Gene Description

PPP2CB encodes the beta isoform of the catalytic subunit of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase (EC 3.1.3.16). PP2Acbeta is the minor catalytic isoform (~97% identical to the alpha isoform PPP2CA, which is ~10x more abundant). The catalytic subunit uses a bimetallic Mn2+ active site to dephosphorylate phosphoserine and phosphothreonine residues on protein substrates. PP2A functions as a heterotrimeric holoenzyme consisting of a scaffold A subunit, catalytic C subunit, and one of many regulatory B subunits that confer substrate specificity and subcellular localization. Combinatorial assembly of subunit isoforms generates >70 distinct PP2A holoenzymes. PP2Acbeta is predominantly cytoplasmic and nuclear, and is also a component of the STRIPAK complex. C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) is a key regulatory mechanism controlling B subunit selection and holoenzyme assembly. PP2A opposes kinase signaling in numerous pathways including cell cycle, Wnt/beta-catenin, Ras/MAPK, NF-kappaB, and PI3K/Akt, and is a major regulator of tau phosphorylation in brain.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0004722 protein serine/threonine phosphatase activity
IBA
GO_REF:0000033
ACCEPT
Summary: PPP2CB is a well-established serine/threonine phosphoprotein phosphatase. This is the core molecular function of the protein, supported by extensive biochemical evidence and phylogenetic analysis across eukaryotes. The IBA annotation is well supported by broad phylogenetic conservation.
Reason: This is the defining molecular function of PPP2CB. The protein catalyzes dephosphorylation of phosphoserine and phosphothreonine residues using a bimetallic active site. Supported by UniProt EC 3.1.3.16 assignment, deep research review, and phylogenetic inference.
Supporting Evidence:
PMID:8206937
Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide.
PMID:2849765
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit.
GO:0000278 mitotic cell cycle
IBA
GO_REF:0000033
ACCEPT
Summary: PP2A holoenzymes (with B55 and B56 regulatory subunits) play essential roles in mitotic cell cycle regulation, opposing CDK-mediated phosphorylation during cell cycle transitions. The IBA annotation is phylogenetically well-supported.
Reason: PP2A is a central regulator of mitotic cell cycle progression. PP2A-B55 and PP2A-B56 are required for mitotic exit, opposing CDK substrates. UniProt lists roles in kinetochore/centromere and spindle pole localization during mitosis. The phylogenetic inference is appropriate.
Supporting Evidence:
PMID:27880917
complementary affinity purification and proximity-based interaction proteomics approaches to generate a physical interactome for 140 human proteins harboring phosphatase catalytic domains
GO:0005829 cytosol
IBA
GO_REF:0000033
ACCEPT
Summary: PPP2CB is active in the cytosol, consistent with its role as a major cytoplasmic phosphatase. The IBA annotation is well supported by both phylogenetic evidence and experimental localization data.
Reason: Cytosolic localization of PP2A catalytic subunits is well established. UniProt lists cytoplasm as a subcellular location for PPP2CB. Reactome pathways also place PPP2CB in cytosol for various signaling events.
Supporting Evidence:
PMID:16541025
PP2A colocalizes with shugoshin at centromeres and is required for centromeric protection.
GO:0000775 chromosome, centromeric region
IEA
GO_REF:0000044
ACCEPT
Summary: IEA annotation derived from UniProt subcellular location vocabulary. UniProt cites PMID:16541025 (Kitajima et al. 2006) showing PP2A localizes to centromeres in prometaphase cells via interaction with SGO1.
Reason: The localization is experimentally supported. UniProt states: "In prometaphase cells, but not in anaphase cells, localizes at centromeres." This is based on PMID:16541025 which directly demonstrated PP2A-SGO1 interaction at centromeres.
Supporting Evidence:
PMID:16541025
a specific subtype of serine/threonine protein phosphatase 2A (PP2A) associating with human shugoshin. PP2A colocalizes with shugoshin at centromeres
GO:0000922 spindle pole
IEA
GO_REF:0000044
ACCEPT
Summary: IEA from UniProt subcellular location. UniProt states PP2A is found at spindle poles during mitosis, based on PMID:16541025.
Reason: Spindle pole localization during mitosis is documented in UniProt subcellular location, which cites PMID:16541025. Consistent with PP2A role in mitotic regulation.
Supporting Evidence:
PMID:16541025
crucial--particularly at centromeres--for proper chromosome segregation in mitosis and meiosis
GO:0004722 protein serine/threonine phosphatase activity
IEA
GO_REF:0000120
ACCEPT
Summary: Combined automated annotation from multiple IEA methods confirming protein serine/threonine phosphatase activity. Redundant with IBA and TAS annotations for the same term but independently valid.
Reason: Correct core function. This IEA annotation is consistent with the more authoritative IBA and TAS annotations for the same GO term.
GO:0005634 nucleus
IEA
GO_REF:0000044
ACCEPT
Summary: IEA from UniProt subcellular location. PPP2CB has been experimentally shown to localize to the nucleus, consistent with its role in nuclear phosphatase activity and its description as predominantly cytoplasmic and nuclear.
Reason: Nuclear localization is well supported. UniProt cites PMID:16541025 and also states PPP2CB is nucleoplasmic (IDA from HPA). Deep research confirms PPP2CB is predominantly cytoplasmic and nuclear.
Supporting Evidence:
PMID:16541025
PP2A colocalizes with shugoshin at centromeres and is required for centromeric protection
GO:0005737 cytoplasm
IEA
GO_REF:0000120
ACCEPT
Summary: IEA annotation for cytoplasm localization. Broader than cytosol but still correct. PPP2CB is well established as a cytoplasmic protein.
Reason: Cytoplasm is a broader parent term of cytosol. PPP2CB is well established in both cytosol and cytoplasm. Consistent with IBA cytosol annotation and UniProt subcellular location.
GO:0016787 hydrolase activity
IEA
GO_REF:0000002
ACCEPT
Summary: IEA from InterPro domain mapping. Hydrolase activity is correct but too general for a protein whose specific phosphatase activity is well characterized. The more specific GO:0004722 annotations exist.
Reason: While very broad, hydrolase activity is technically correct as a parent of phosphatase activity. The more specific GO:0004722 annotations also exist. This IEA is acceptable as a domain-based annotation even though more informative terms are present.
GO:0090443 FAR/SIN/STRIPAK complex
IEA
GO_REF:0000117
ACCEPT
Summary: IEA from ARBA machine learning model predicting STRIPAK complex membership. This is consistent with experimental evidence from PMID:18782753 (IDA annotation also present).
Reason: Correct annotation. PPP2CB was experimentally identified as part of the STRIPAK complex in PMID:18782753, and a separate IDA annotation exists. This IEA is redundant but valid.
GO:0005515 protein binding
IPI
PMID:10698523
GSK-3beta-dependent phosphorylation of adenomatous polyposis...
MARK AS OVER ANNOTATED
Summary: IPI based on interaction with AXIN2 (Q9Y2T1). The study showed PP2A complexed with Axin dephosphorylates APC in Wnt signaling. The interaction is functionally meaningful (Wnt pathway regulation) but annotated as generic protein binding.
Reason: Protein binding is uninformative. The interaction with AXIN2 reflects PP2A recruitment to the beta-catenin destruction complex. A more informative annotation would capture the specific functional context (e.g., phosphatase activity in the Wnt pathway), but that is a BP annotation, not MF. The IPI evidence does not support a more specific MF term than protein binding.
Supporting Evidence:
PMID:10698523
the heterodimeric form of protein phosphatase 2A (PP2A) directly bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated by GSK-3beta
GO:0005515 protein binding
IPI
PMID:16085932
A novel, evolutionarily conserved protein phosphatase comple...
MARK AS OVER ANNOTATED
Summary: IPI based on interaction with TIPRL (O75663). The study characterized a PP4 complex involved in cisplatin sensitivity. TIPRL is a known PP2A interactor and phosphatase regulator. Annotated as generic protein binding.
Reason: Protein binding is uninformative. TIPRL interaction with PP2A catalytic subunits is part of the phosphatase regulatory network, but the GO term does not capture the functional significance. The primary study focused on PP4, not PP2A.
Supporting Evidence:
PMID:16085932
Using a combination of tandem affinity purification tagging and mass spectrometry, we characterized a novel, evolutionarily conserved protein phosphatase 4 (PP4)-containing complex
GO:0005515 protein binding
IPI
PMID:18782753
A PP2A phosphatase high density interaction network identifi...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with IGBP1/alpha4 (P78318) and STRIP1 (Q5VSL9) from the PP2A high-density interaction network study that defined the STRIPAK complex. These are well-established PP2A complex components.
Reason: Protein binding is uninformative. Both IGBP1 and STRIP1 are functional PP2A-associated proteins. The interactions are better captured by the STRIPAK complex (GO:0090443) and PP2A complex (GO:0000159) annotations.
Supporting Evidence:
PMID:18782753
STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2
GO:0005515 protein binding
IPI
PMID:19156129
An integrated workflow for charting the human interaction pr...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with IGBP1 (P78318) from an integrated PP2A interaction proteomics workflow. This is a well-characterized PP2A regulatory interaction.
Reason: Protein binding is uninformative. IGBP1/alpha4 is a known PP2A chaperone/regulatory protein. Better captured by complex membership annotations.
GO:0005515 protein binding
IPI
PMID:20969868
LIM domain protein FHL1B interacts with PP2A catalytic β sub...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with FHL1B (Q13642-2). Study demonstrated FHL1B specifically interacts with PP2A catalytic beta subunit (PPP2CB) by yeast two-hybrid and co-immunoprecipitation, suggesting a novel cell-cycle regulatory pathway.
Reason: Protein binding is uninformative. The FHL1B interaction is PPP2CB-specific (not shown for PPP2CA) and linked to cell cycle regulation, which is interesting but the GO term does not capture this specificity.
Supporting Evidence:
PMID:20969868
FHL1B was demonstrated to interact with the beta catalytic subunit (Cbeta) of a type 2A protein phosphatase (PP2A) by yeast two-hybrid screening
GO:0005515 protein binding
IPI
PMID:25531779
STRIPAK components determine mode of cancer cell migration a...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with STRIP1 (Q5VSL9) from STRIPAK complex study on cancer cell migration and metastasis. High-throughput proteomics study.
Reason: Protein binding is uninformative. STRIP1 interaction is part of STRIPAK complex, better captured by GO:0090443.
GO:0005515 protein binding
IPI
PMID:26496610
A human interactome in three quantitative dimensions organiz...
MARK AS OVER ANNOTATED
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from quantitative human interactome study. Large-scale proteomics.
Reason: Protein binding is uninformative. Both are known PP2A complex components. High-throughput study; interactions better captured by complex annotations.
GO:0005515 protein binding
IPI
PMID:27880917
Phenotypic and Interaction Profiling of the Human Phosphatas...
MARK AS OVER ANNOTATED
Summary: IPI for interactions with TIPRL (O75663) and IGBP1 (P78318) from comprehensive phosphatase interactome profiling. Study identified diverse mitotic regulators among phosphatase interactors.
Reason: Protein binding is uninformative. Both TIPRL and IGBP1 are established PP2A regulators. The study provides valuable interactome data but protein binding does not convey functional information.
Supporting Evidence:
PMID:27880917
complementary affinity purification and proximity-based interaction proteomics approaches to generate a physical interactome for 140 human proteins harboring phosphatase catalytic domains
GO:0005515 protein binding
IPI
PMID:28514442
Architecture of the human interactome defines protein commun...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with STRIP1 (Q5VSL9) from architecture of the human interactome study. Large-scale proteomics.
Reason: Protein binding is uninformative. STRIP1 is a STRIPAK component. High-throughput study.
GO:0005515 protein binding
IPI
PMID:32814053
Interactome Mapping Provides a Network of Neurodegenerative ...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with FMR1/FMRP (Q06787-7) from neurodegenerative disease interactome mapping study. The interaction was identified by mass spectrometry in a large-scale screen.
Reason: Protein binding is uninformative. The FMR1 interaction is from a high-throughput screen and the functional significance for PPP2CB is unclear. PP2A may dephosphorylate FMRP but this is not demonstrated in this study.
Supporting Evidence:
PMID:32814053
Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains
GO:0005515 protein binding
IPI
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling...
MARK AS OVER ANNOTATED
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from dual proteome-scale cell-specific interactome study.
Reason: Protein binding is uninformative. Both are established PP2A complex members. High-throughput study.
GO:0005515 protein binding
IPI
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human ce...
MARK AS OVER ANNOTATED
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from the OpenCell endogenous tagging study. Large-scale proteomics.
Reason: Protein binding is uninformative. Both are known PP2A/STRIPAK complex members. High-throughput study.
GO:0005515 protein binding
IPI
PMID:9647778
Alpha 4 associates with protein phosphatases 2A, 4, and 6.
MARK AS OVER ANNOTATED
Summary: IPI for interaction with IGBP1/alpha4 (P78318). Study demonstrated alpha4 associates constitutively with both PP2A catalytic isoforms, PP4C, and PP6C. This is a well-established functional interaction where alpha4 serves as a chaperone protecting monomeric PP2A C subunit.
Reason: Protein binding is uninformative. The alpha4-PP2Ac interaction is functionally important for PP2A biogenesis and stability. However, the GO term protein binding does not capture this functional role.
Supporting Evidence:
PMID:9647778
alpha 4, a previously identified phosphoprotein, associates constitutively with the catalytic subunits of PP4, PP6, and both isoforms of PP2A
GO:0000159 protein phosphatase type 2A complex
IEA
GO_REF:0000107
ACCEPT
Summary: IEA from Ensembl Compara transfer from mouse PPP2CB. PPP2CB is a catalytic subunit of the PP2A holoenzyme complex, which is its primary functional context.
Reason: Core annotation. PPP2CB is a defining component of the PP2A holoenzyme complex. Strongly supported by extensive biochemical and structural evidence. Also has a TAS annotation (PMID:8206937).
GO:0004721 phosphoprotein phosphatase activity
IEA
GO_REF:0000107
ACCEPT
Summary: IEA from Ensembl Compara. Phosphoprotein phosphatase activity is a parent term of protein serine/threonine phosphatase activity (GO:0004722). Correct but less specific than GO:0004722.
Reason: Technically correct as PPP2CB does have phosphoprotein phosphatase activity. More specific GO:0004722 annotations are also present. This broader IEA is acceptable.
GO:0010288 response to lead ion
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: IEA transferred from rat PPP2CB (P62716) via Ensembl Compara. Based on rat studies showing PP2A activity is affected by lead exposure. Duplicate with ISS annotation below.
Reason: Response to lead ion is not a core function of PPP2CB. Lead ions can inhibit PP2A activity (as they affect many metalloenzymes), but this is a toxicological response rather than a primary biological function. Keeping as non-core given the supporting evidence from rat studies.
GO:0031113 regulation of microtubule polymerization
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A regulates microtubule dynamics through dephosphorylation of MAPs (MAP1b, MAP2, tau). This is consistent with PP2A's role in cytoskeletal regulation.
Reason: PP2A regulates microtubule polymerization indirectly by dephosphorylating microtubule-associated proteins. PMID:10640627 showed PP2A regulates MAP1b and MAP2 phosphorylation and their microtubule binding activity. This is a downstream consequence of PP2A phosphatase activity rather than a core function of PPP2CB specifically.
Supporting Evidence:
PMID:10640627
The inhibition of PP2A, and to a lesser extent of PP2B, was found to induce an increased phosphorylation of MAP1b and inhibit its microtubule binding activity
GO:0044325 transmembrane transporter binding
IEA
GO_REF:0000107
UNDECIDED
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A interacts with various membrane transporters and channels to regulate their phosphorylation state. Limited direct evidence for PPP2CB specifically.
Reason: The evidence for transmembrane transporter binding is based on computational transfer from rat. While PP2A can regulate transporter phosphorylation, the specificity and directness of a binding interaction is not well documented for PPP2CB specifically. Unable to verify the original rat experimental evidence.
GO:0046580 negative regulation of Ras protein signal transduction
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A dephosphorylates components of the Ras/MAPK pathway, acting as a negative regulator. This is well established for PP2A holoenzymes generally.
Reason: PP2A is well established as a negative regulator of Ras/MAPK signaling, including dephosphorylation of RAF and ERK pathway components. However, this represents one of many PP2A-regulated pathways and is driven by specific B subunit combinations rather than PPP2CB specifically. Deep research review confirms PP2A antagonizes Ras/MAPK signaling.
GO:0005654 nucleoplasm
IDA
GO_REF:0000052
ACCEPT
Summary: IDA from HPA immunofluorescence data. PPP2CB was detected in nucleoplasm by immunofluorescence. Consistent with UniProt subcellular location annotation showing nuclear localization.
Reason: Nucleoplasm localization is experimentally supported by HPA immunofluorescence and consistent with UniProt subcellular location showing nuclear localization (PMID:16541025). Deep research also describes PPP2CB as predominantly cytoplasmic and nuclear.
GO:1902996 regulation of neurofibrillary tangle assembly
TAS
PMID:16262633
Contributions of protein phosphatases PP1, PP2A, PP2B and PP...
KEEP AS NON CORE
Summary: TAS annotation based on a study showing PP2A is the major tau phosphatase in human brain (~71% of total tau phosphatase activity), and PP2A activity is decreased in AD brain, correlating with tau hyperphosphorylation and neurofibrillary tangle formation.
Reason: While PP2A is clearly the major tau phosphatase, this represents a downstream physiological consequence of PP2A phosphatase activity in brain rather than a core function of PPP2CB. Additionally, the study used PP2A generally (likely predominantly PPP2CA given its higher expression in brain). The annotation is not wrong but represents a non-core, tissue-specific function.
Supporting Evidence:
PMID:16262633
PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain
GO:0043124 negative regulation of canonical NF-kappaB signal transduction
IGI
PMID:28159925
miRNA-1246 induces pro-inflammatory responses in mesenchymal...
KEEP AS NON CORE
Summary: IGI annotation from a study showing miR-1246 directly targets PPP2CB, and PPP2CB knockdown increases p65/NF-kappaB levels in MSCs. The IGI evidence is based on interaction with RELA/p65 (Q04206).
Reason: The study provides evidence that PPP2CB negatively regulates NF-kappaB signaling, but in a specific cellular context (MSCs in tumor microenvironment). PPP2CB knockdown increased RELA expression and total p65 levels but did not directly increase phospho-p65. The effect on pro-inflammatory cytokines required additional TNFalpha stimulation. This represents a non-core, context-dependent function.
Supporting Evidence:
PMID:28159925
Knock-down of PPP2CB significantly increased RELA expression
PMID:28159925
knock-down of either PRKAR1A or PPP2CB led to a significant up-regulation of total p65 in MSCs whereas phosphorylation of p65 at Ser536 remained unaffected
GO:0090443 FAR/SIN/STRIPAK complex
IDA
PMID:18782753
A PP2A phosphatase high density interaction network identifi...
ACCEPT
Summary: IDA annotation showing PPP2CB is part of the STRIPAK complex, based on iterative affinity purification/mass spectrometry in human cells. The study defined the STRIPAK complex and identified PPP2CB as a core component.
Reason: Well-supported experimental evidence. The study used iterative AP-MS to identify PPP2CB in the STRIPAK complex, which contains PP2A catalytic and scaffolding subunits, striatins, MOB4, STRIP1/2, PDCD10, and STE20 kinases. This is a core complex for PPP2CB function.
Supporting Evidence:
PMID:18782753
STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2
GO:0010629 negative regulation of gene expression
IGI
PMID:28159925
miRNA-1246 induces pro-inflammatory responses in mesenchymal...
MARK AS OVER ANNOTATED
Summary: IGI annotation (with TNFalpha P01375) showing PPP2CB acts upstream of negative regulation of gene expression. Based on the miR-1246/PPP2CB study in MSCs where PPP2CB knockdown combined with TNFalpha enhanced expression of pro-inflammatory genes.
Reason: This annotation is overly broad. The study showed PPP2CB knockdown combined with TNFalpha increases IL-6, CCL2, CCL5 transcription in MSCs. This means PPP2CB normally negatively regulates expression of these specific inflammatory genes, but the term "negative regulation of gene expression" is too generic. Additionally, the qualifier is acts_upstream_of rather than involved_in, indicating indirect effects.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB in combination with TNFalpha stimulation phenocopied the miR-1246-enhanced transcriptional response of IL-6
GO:0010629 negative regulation of gene expression
IMP
PMID:28159925
miRNA-1246 induces pro-inflammatory responses in mesenchymal...
MARK AS OVER ANNOTATED
Summary: IMP annotation showing PPP2CB is involved in negative regulation of gene expression, based on the same miR-1246 study in MSCs.
Reason: Same concern as the IGI annotation above. The term is too broad. The evidence shows PPP2CB normally suppresses inflammatory gene expression in MSCs, but this is a very general biological process annotation that does not capture specificity. The NF-kappaB annotation (GO:0043124) is more specific and informative.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB significantly decreased releases of IL-6 and CCL2
GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway
IGI
PMID:28159925
miRNA-1246 induces pro-inflammatory responses in mesenchymal...
KEEP AS NON CORE
Summary: IGI annotation showing PPP2CB acts upstream of negative regulation of TNF-mediated signaling. Based on the miR-1246 study where PPP2CB knockdown combined with TNFalpha enhances inflammatory responses.
Reason: The evidence supports that PPP2CB negatively regulates TNF-mediated signaling in MSCs. PPP2CB knockdown released negative feedback on IL-6 transcription after TNFalpha stimulation. However, this is a context-dependent effect in MSCs and represents a non-core function.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB in combination with TNFalpha stimulation phenocopied the miR-1246-enhanced transcriptional response of IL-6 in combination with TNFalpha
GO:0004722 protein serine/threonine phosphatase activity
TAS
PMID:8206937
The catalytic subunit of protein phosphatase 2A is carboxyl-...
ACCEPT
Summary: TAS annotation from the study that demonstrated carboxyl methylation of PP2A catalytic subunit in vivo. The paper confirms PP2Ac phosphatase activity toward phosphorylase a and phosphopeptide substrates.
Reason: Core molecular function, directly supported by the cited publication which demonstrated PP2Ac enzymatic activity.
Supporting Evidence:
PMID:8206937
Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide
GO:0048156 tau protein binding
NAS
PMID:28386764
Roles of tau protein in health and disease.
KEEP AS NON CORE
Summary: NAS annotation based on a comprehensive review of tau protein roles in health and disease. PP2A is well established as the major tau phosphatase, which implies physical binding to tau.
Reason: PP2A does bind and dephosphorylate tau protein, but this is primarily documented for PP2A holoenzymes in brain (likely predominantly PPP2CA-containing). The NAS evidence from a review article is weak. Tau binding is a substrate interaction for PP2A rather than a core binding function. Keeping as non-core given that PP2A-tau interaction is well established in the broader literature.
Supporting Evidence:
PMID:28386764
Tau is well established as a microtubule-associated protein in neurons
PMID:16262633
PP2A is the major tau phosphatase that regulates its phosphorylation at multiple sites in human brain
GO:0010288 response to lead ion
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation transferred from rat PPP2CB (P62716) by curator judgment. PP2A activity can be affected by lead exposure, as lead interferes with the metalloenzyme's active site.
Reason: Consistent with the IEA annotation for the same term. Response to lead ion is a toxicological response rather than a core function. The ISS transfer from rat is appropriate given near-identical sequence.
GO:0004722 protein serine/threonine phosphatase activity
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation transferred from rat PPP2CB (P62716). Core phosphatase activity, redundant with other annotations for the same term.
Reason: Correct core function. ISS transfer from rat is fully appropriate given near-100% sequence identity between human and rat PPP2CB.
GO:0004722 protein serine/threonine phosphatase activity
TAS
PMID:10640627
Regulation of phosphorylation of neuronal microtubule-associ...
ACCEPT
Summary: TAS annotation from a study on PP2A regulation of MAP1b and MAP2 phosphorylation in rat brain. Confirms PP2A serine/threonine phosphatase activity toward neuronal substrates.
Reason: Core molecular function. The study directly demonstrated PP2A phosphatase activity toward MAP substrates.
Supporting Evidence:
PMID:10640627
PP2A might be the major PP that participates in regulation of the phosphorylation of MAP1b and MAP2 and their biological activities
GO:0004722 protein serine/threonine phosphatase activity
TAS
PMID:16262633
Contributions of protein phosphatases PP1, PP2A, PP2B and PP...
ACCEPT
Summary: TAS annotation from the tau phosphorylation study. PP2A accounts for ~71% of tau phosphatase activity in human brain.
Reason: Core molecular function. The study quantitatively demonstrated PP2A phosphatase activity toward tau.
Supporting Evidence:
PMID:16262633
PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain
GO:0005829 cytosol
TAS
Reactome:R-HSA-1295599
ACCEPT
Summary: TAS from Reactome pathway for SPRY2 translocation to plasma membrane. Places PPP2CB in cytosol as part of Spry regulation of FGF signaling.
Reason: Cytosol localization is correct and well-supported. Reactome annotation reflects PPP2CB involvement in SPRY2/FGF signaling regulation in the cytosol.
GO:0005829 cytosol
TAS
Reactome:R-HSA-1295609
ACCEPT
Summary: TAS from Reactome pathway for SRC phosphorylation of SPRY2. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid from Reactome evidence.
GO:0005829 cytosol
TAS
Reactome:R-HSA-1295613
ACCEPT
Summary: TAS from Reactome pathway for SPRY2-GRB2 binding. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid.
GO:0005829 cytosol
TAS
Reactome:R-HSA-1295622
ACCEPT
Summary: TAS from Reactome pathway for SPRY2-CBL binding. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid.
GO:0005829 cytosol
TAS
Reactome:R-HSA-1295632
ACCEPT
Summary: TAS from Reactome pathway for PP2A dephosphorylation of SPRY2. This directly reflects PP2A phosphatase activity in the cytosol acting on the SPRY2 substrate.
Reason: Cytosol localization is correct and directly relevant to PP2A function. This Reactome entry describes the actual dephosphorylation reaction catalyzed by PP2A on SPRY2.
GO:0005829 cytosol
TAS
Reactome:R-HSA-1549564
ACCEPT
Summary: TAS from Reactome pathway for PTPN11 dephosphorylation of SPRY2. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations.
GO:0005829 cytosol
TAS
Reactome:R-HSA-934559
ACCEPT
Summary: TAS from Reactome pathway for SPRY2 phosphorylation by MNK1. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations.
GO:0005515 protein binding
IPI
PMID:21784977
Zinc finger protein tristetraprolin interacts with CCL3 mRNA...
MARK AS OVER ANNOTATED
Summary: IPI for interaction with TTP/ZFP36 (P26651). The study focused on TTP regulation of CCL3 mRNA and tissue inflammation. The interaction with PPP2CB was likely identified as part of a broader interactome screen.
Reason: Protein binding is uninformative. The TTP-PPP2CB interaction may reflect PP2A regulation of TTP phosphorylation (TTP activity is regulated by phosphorylation), but the study focused on TTP-mRNA interactions, not PP2A function.
Supporting Evidence:
PMID:21784977
Zinc finger protein tristetraprolin (TTP) modulates macrophage inflammatory activity by destabilizing cytokine mRNAs
GO:0000159 protein phosphatase type 2A complex
TAS
PMID:8206937
The catalytic subunit of protein phosphatase 2A is carboxyl-...
ACCEPT
Summary: TAS annotation from the carboxyl-methylation study, which demonstrated PP2A exists as a complex with methylated catalytic subunit. The study worked with PP2A holoenzyme from MCF7 cells.
Reason: Core annotation. PPP2CB is a defining component of the PP2A complex. The study directly worked with PP2A holoenzyme complexes.
Supporting Evidence:
PMID:8206937
Treatment of extracts from human breast cancer (MCF7) cells with either alkali or ethanol increased immunoreactivity of PP2Ac subunit severalfold
GO:0006470 protein dephosphorylation
TAS
PMID:2849765
The nucleotide sequence of the cDNA encoding the human lung ...
ACCEPT
Summary: TAS annotation from the original cDNA cloning paper for human PPP2CB. The paper established PPP2CB as a phosphatase catalytic subunit.
Reason: Core biological process. Protein dephosphorylation is the fundamental reaction catalyzed by PPP2CB. This is directly supported by the identification of PPP2CB as a PP2A catalytic subunit.
Supporting Evidence:
PMID:2849765
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit
GO:0046872 metal ion binding
IEA
GO_REF:0000043
NEW
Summary: PPP2CB requires two Mn2+ ions at its active site for catalytic activity. Metal ion binding is inherent to its phosphatase mechanism. This annotation is present in UniProt GO lines but was not in the GOA TSV extract; adding as it appears in UniProt.
Reason: PPP2CB uses a bimetallic Mn2+ active site for catalysis. UniProt lists multiple Mn2+ binding sites (residues 57, 59, 85, 117, 167, 241) and includes metal ion binding as a GO annotation. This is a core aspect of the catalytic mechanism.
Supporting Evidence:
PMID:10318862
substitution of glutamine for either of two putative active site histidines in the PP2A C subunit results in inactivation of PP2A

Core Functions

PPP2CB is the beta catalytic subunit of PP2A, a major cellular Ser/Thr phosphatase (EC 3.1.3.16). It dephosphorylates phosphoserine and phosphothreonine residues on protein substrates using a bimetallic Mn2+ active site. PPP2CB functions as the catalytic engine of heterotrimeric PP2A holoenzymes (A scaffold + C catalytic + B regulatory subunit). Substrate specificity is determined by the regulatory B subunit incorporated into the holoenzyme. PPP2CB is the minor catalytic isoform (~97% identical to PPP2CA but ~10x less abundant), and is predominantly cytoplasmic and nuclear. C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) regulates holoenzyme assembly and B subunit selection.

Supporting Evidence:
  • PMID:8206937
    Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide.
  • PMID:2849765
    The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit.
  • PMID:16262633
    PP2A accounted for approximately 71% of the total tau phosphatase activity of human brain.

PPP2CB functions as the catalytic subunit within the STRIPAK complex (FAR/SIN/STRIPAK complex), a large signaling assembly that includes PP2A catalytic and scaffolding subunits, striatins (B''' regulatory subunits), MOB4, STRIP1/2, PDCD10/CCM3, and germinal center kinase III family STE20 kinases. In this context, PPP2CB provides phosphatase activity that opposes the kinase activities within the complex, regulating cell migration, polarity, and cerebral cavernous malformation signaling.

Supporting Evidence:
  • PMID:18782753
    STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2, PDCD10, and members of the germinal center kinase III family of Ste20 kinases.

References

Gene Ontology annotation through association of InterPro records with GO terms
Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping, accompanied by conservative changes to GO terms applied by UniProt
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Gene Ontology annotation based on curation of immunofluorescence data
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit.
  • Original cDNA cloning and sequencing of human PPP2CB from lung tissue.
The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo.
  • Demonstrated carboxyl-methylation of PP2Ac at Leu-309 in vivo; methylation increases phosphatase activity.
Alpha 4 associates with protein phosphatases 2A, 4, and 6.
  • Alpha4/IGBP1 constitutively associates with PP2A, PP4, and PP6 catalytic subunits.
A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A.
  • Identified PME-1 as PP2A demethylase; H59Q and H118Q mutations inactivate PP2A catalytic activity.
Regulation of phosphorylation of neuronal microtubule-associated proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain.
  • PP2A is the major phosphatase regulating MAP1b and MAP2 phosphorylation and microtubule binding activity.
GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin.
  • PP2A directly binds Axin and dephosphorylates APC phosphorylated by GSK-3beta in Wnt signaling.
A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity.
  • Characterized PP4-containing complex; TIPRL interacts with PP2A family catalytic subunits.
Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation.
  • PP2A accounts for ~71% of total tau phosphatase activity in human brain; activity decreased in AD brain.
Shugoshin collaborates with protein phosphatase 2A to protect cohesin.
  • PP2A localizes to centromeres in prometaphase via SGO1 interaction; also found at spindle poles during mitosis.
A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein.
  • Defined the STRIPAK complex containing PP2A catalytic/scaffolding subunits, striatins, MOB4, STRIP1/2, PDCD10, and STE20 kinases.
An integrated workflow for charting the human interaction proteome: insights into the PP2A system.
  • Mapped the PP2A interaction network including IGBP1/alpha4 binding to PP2A catalytic subunits.
LIM domain protein FHL1B interacts with PP2A catalytic β subunit--a novel cell cycle regulatory pathway.
  • FHL1B specifically interacts with PPP2CB (not PPP2CA was tested) by yeast two-hybrid and co-IP; linked to cell cycle regulation.
Zinc finger protein tristetraprolin interacts with CCL3 mRNA and regulates tissue inflammation.
  • TTP/ZFP36 interacts with PPP2CB; TTP modulates inflammatory cytokine mRNA stability.
STRIPAK components determine mode of cancer cell migration and metastasis.
  • STRIPAK complex components including STRIP1 interact with PP2A catalytic subunits in cancer cell migration.
A human interactome in three quantitative dimensions organized by stoichiometries and abundances.
  • High-throughput interactome study confirming IGBP1 and STRIP1 interactions with PPP2CB.
Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.
  • Comprehensive phosphatase interactome profiling; PPP2CB interacts with TIPRL and IGBP1.
miRNA-1246 induces pro-inflammatory responses in mesenchymal stem/stromal cells by regulating PKA and PP2A.
  • PPP2CB is a direct target of miR-1246; knockdown increases p65/NF-kappaB and enhances TNF-mediated inflammatory gene expression in MSCs.
Roles of tau protein in health and disease.
  • Review describing PP2A as a major tau phosphatase, with relevance to tauopathies.
Architecture of the human interactome defines protein communities and disease networks.
  • Large-scale interactome study confirming STRIP1 interaction with PPP2CB.
Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
  • Identified PPP2CB-FMR1 interaction in neurodegenerative disease protein network.
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
  • Cell-specific interactome confirming IGBP1 and STRIP1 interactions with PPP2CB.
OpenCell: Endogenous tagging for the cartography of human cellular organization.
  • Endogenous tagging proteomics confirming IGBP1 and STRIP1 interactions with PPP2CB.
Reactome:R-HSA-1295599
SPRY2 translocates to the plasma membrane
Reactome:R-HSA-1295609
SRC phosphorylates SPRY2 on Y55 and Y227
Reactome:R-HSA-1295613
SPRY2 binds GRB2
Reactome:R-HSA-1295622
SPRY2 binds CBL
Reactome:R-HSA-1295632
PPA2A dephosphorylates SPRY2
Reactome:R-HSA-1549564
PPTN11 dephosphorylates SPRY2
Reactome:R-HSA-934559
SPRY2 is phosphorylated by phosphorylated MNK1

Deep Research

Falcon

(PPP2CB-deep-research-falcon.md)
Comprehensive Research Report: Human **PPP2CB** (UniProt **P62714**) — Functional Annotation and Translational Context Falcon Edison Scientific Literature 46 citations 2026-03-07T19:37:51.307717

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human PPP2CB (UniProt P62714) — Functional Annotation and Translational Context

0. Gene/protein identity verification (mandatory)

The literature reviewed matches the UniProt-provided target:

  • UniProt P62714 maps to PP2A catalytic subunit beta (PP2Acβ), encoded by PPP2CB in Homo sapiens (human). This mapping is explicitly shown in a curated serine/threonine phosphatase family compendium table that associates PP2Acβ/PPP2CB with P62714. (cohen2010phosphatasefamiliesdephosphorylating pages 5-6)
  • PP2A catalytic subunits exist as two highly similar isoforms (α and β) encoded by PPP2CA and PPP2CB, with ~97% sequence similarity/identity reported in multiple authoritative reviews. (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)

These checks support that the evidence below pertains to the intended human PPP2CB protein, rather than a paralog or non-human homolog. (cohen2010phosphatasefamiliesdephosphorylating pages 5-6, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)

1. Key concepts and definitions (current understanding)

1.1 What PPP2CB encodes

PPP2CB encodes the catalytic Cβ subunit of protein phosphatase 2A (PP2A), a major member of the PPP family of serine/threonine phosphatases. PP2A catalytic subunits (PPP2CA/PPP2CB) are extremely conserved across eukaryotes and contribute to the bulk of Ser/Thr dephosphorylation in cells when assembled into regulated holoenzymes. (cohen2010phosphatasefamiliesdephosphorylating pages 8-9, kokot2022emerginginsightsinto pages 1-2)

1.2 PP2A as a holoenzyme system (architecture drives specificity)

PP2A is typically a heterotrimeric holoenzyme composed of:

  • A (scaffold) subunit
  • C (catalytic) subunit (PPP2CA or PPP2CB)
  • B (regulatory) subunit (multiple families)

This A–C–B architecture is repeatedly emphasized as the key determinant of specificity: regulatory B subunits largely determine substrate specificity and subcellular localization. (nasa2020effectsofcarboxylterminal pages 1-3, peris2023regulationandrole pages 1-2)

Quantitatively, reviews summarize that combinatorial assembly yields >70–90 (and up to ~100) distinct PP2A holoenzymes, depending on how B-subunit isoforms/splice variants are counted. (cohen2010phosphatasefamiliesdephosphorylating pages 7-8, nasa2020effectsofcarboxylterminal pages 1-3, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)

1.3 Enzymatic activity and catalytic chemistry (mechanistic understanding)

PP2A catalytic subunits are metal-dependent phosphoprotein phosphatases. Mechanistic descriptions from modern modeling and review sources converge on a bimetal active site (M1/M2) that coordinates the substrate phosphate and activates a bridging hydroxide (W1(OH−)) that attacks the phosphorus atom during hydrolysis of phospho-Ser/Thr bonds. (salter2023quantumbasedmodelingimplies pages 1-2, kokot2022emerginginsightsinto pages 6-7)

A 2023 quantum-based modeling analysis further proposes that a conserved catalytic-subunit arginine (Arg89) can enhance catalysis by bidentate binding to the substrate phosphate, lowering the computed activation barrier from 18.8 kcal/mol (Arg89 sequestered) to 15.5 kcal/mol (bidentate Arg89–substrate binding). (salter2023quantumbasedmodelingimplies pages 1-2)

1.4 Substrate and phosphorylation-site selection: motifs plus docking

A 2023 Trends in Biochemical Sciences review synthesizes current thinking that PPP phosphatase specificity arises from both:

  1. Active-site motif preferences and chemistry
  2. Docking interactions via regulatory subunits (short linear motifs/SLiMs and distal interactions)

For PP2A holoenzymes, B subunits are central: acidic patches on B55/B56 can promote dephosphorylation of sites with surrounding basic residues; B55 is discussed as targeting proline-directed sites (pSP/pTP) in specific conformations and can be regulated by prolyl isomerization. (nguyen2023substrateandphosphorylation pages 3-4)

2. PPP2CB-specific function in cells (what is known; what is inferred)

2.1 Catalytic isoform non-redundancy and expression balance

Multiple sources emphasize that although PPP2CA and PPP2CB are very similar (~97%), they are not fully redundant and can differ by expression patterns and functional context. (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)

In brain-related contexts, expression of Cα is generally higher than Cβ, suggesting PPP2CB may contribute a smaller fraction of total PP2A catalytic capacity in many settings but still be functionally important where it is expressed or recruited into specific holoenzymes. (verbinnen2021proteinphosphatase2a pages 1-5)

2.2 Subcellular localization of PP2Acβ (PPP2CB)

A therapeutics-focused PP2A review states that catalytic isoforms differ in localization: Cα (PPP2CA) is enriched at the plasma membrane, whereas Cβ (PPP2CB) is predominantly cytoplasmic and nuclear. (baskaran2018proteinphosphatase2a pages 6-10)

This provides a plausible functional axis for PPP2CB annotation: PPP2CB-containing holoenzymes may contribute disproportionately to nuclear and cytoplasmic dephosphorylation events, depending on recruited B subunits and signaling context. (baskaran2018proteinphosphatase2a pages 6-10, peris2023regulationandrole pages 1-2)

2.3 Regulation of PPP2CB function via holoenzyme assembly controls

Key regulatory principles apply to both catalytic isoforms (and are typically described for PP2A-Cα but explicitly framed as PP2Acα/β in several sources):

  • C-terminal Leu309 methylation biases B-subunit selection and stabilizes specific heterotrimers; methylation is catalyzed by LCMT1 and reversed by PME-1/PME1. (nasa2020effectsofcarboxylterminal pages 1-3, peris2023regulationandrole pages 2-4)
  • PME-1 binding can reduce PP2A activity by rearranging the active site and displacing catalytic metal ions, connecting methylation control to catalytic competence. (peris2023regulationandrole pages 2-4)
  • PP2A catalytic subunit assembly/activation involves biogenesis factors including α4 (protection of monomeric C) and PTPA (activation/metal loading). (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)

3. Recent developments and latest research (prioritizing 2023–2024)

3.1 2024 structural/allosteric breakthrough: PP2A-B56δ autoinhibition via disordered arms

A 2024 PNAS study provides cryo-EM structures of PP2A-B56δ showing that B56δ contains long intrinsically disordered N/C-terminal arms that fold back onto the holoenzyme, forming a dynamic interface spanning >190 Å. This interface occludes the active site/substrate-binding region and stabilizes a closed, autoinhibited state, providing a concrete structural model for regulation by phosphorylation and for disease-mutation effects (Jordan’s syndrome; PPP2R5D variants). (wu2024b56δlongdisorderedarms pages 1-2)

Although this work focuses on the regulatory subunit PPP2R5D, it explicitly frames the catalytic core as PP2Ac (PPP2CA/PPP2CB) and thus is directly relevant to PPP2CB-containing holoenzymes operating with B56δ. (wu2024b56δlongdisorderedarms pages 1-2)

3.2 2023 synthesis of PP2A-B56 regulation in cancer: emphasis on C-tail PTMs and PME-1/PTPA

A 2023 BBA Reviews on Cancer article summarizes how PP2A-B56 tumor suppressor functions depend on regulated holoenzyme assembly, strongly influenced by C-terminal tail modifications (phosphorylation and Leu309 methylation) and by assembly factors such as PTPA and PME-1. It also highlights that PME-1 can directly suppress PP2A by displacing metal ions from the active site, adding mechanistic depth beyond “methylation changes binding.” (peris2023regulationandrole pages 2-4)

3.3 2023 framework for modern phosphatase specificity

The 2023 TiBS review emphasizes that PPP holoenzymes (including PP2A with PPP2CA/PPP2CB) achieve specificity via combined consensus motifs and SLiM docking, and that modern mass spectrometry approaches are transforming substrate mapping. (nguyen2023substrateandphosphorylation pages 1-3)

3.4 2024 disease-proteomics signal explicitly calling out PPP2CB (biomarker hypothesis)

A 2024 Scientific Reports study using plasma and duodenal proteomics in celiac disease identified PPP2CB as one of four plasma proteins selected by three machine-learning methods (alongside FABP, CPOX, BHMT) as potentially associated with pathological grading (Marsh classification/villous atrophy). (li2024proteomicanalysisof pages 6-8, li2024proteomicanalysisof pages 9-10)

Notably, the same analysis reports that PPP2CB’s ROC performance was limited in that cohort: AUC 0.5661 with 95% CI 0.4225–0.7097 and P>0.05, indicating that PPP2CB is best interpreted as a hypothesis-generating feature rather than a validated biomarker. (li2024proteomicanalysisof pages 6-8)

4. Pathways and biological processes most directly supported by evidence

Because PPP2CB encodes a catalytic subunit that functions within many alternative PP2A holoenzymes, pathway attribution is best made at the holoenzyme-family level (B55, B56, etc.), with PPP2CB contributing as the catalytic engine when present.

4.1 Cell cycle control and mitotic exit (B55/B56-driven specificity)

Reviews emphasize that PP2A-B55 and PP2A-B56 oppose kinase signaling during cell-cycle transitions, with substrate selection shaped by B-subunit docking and motif preferences; PP2A-B55 is frequently discussed in the context of proline-directed sites and basic-residue recognition, while B56 recognizes LxxIxE motifs in substrates. (nguyen2023substrateandphosphorylation pages 3-4, verbinnen2021proteinphosphatase2a pages 1-5)

The 2024 PNAS B56δ structural study links regulation to phosphorylation-dependent activation and mitotic defects caused by disease variants, reinforcing mitotic control as an area where PP2A catalytic subunits (including PPP2CB) are functionally deployed. (wu2024b56δlongdisorderedarms pages 1-2)

4.2 Cancer signaling pathway opposition and therapeutic rationale

Cancer-focused sources describe PP2A as a central antagonist of oncogenic pathways, with relevance to PI3K/Akt, Ras/MAPK, Wnt/β-catenin, Myc, NF-κB, and mTOR signaling; dysregulation frequently occurs via altered holoenzyme composition or inhibition by proteins such as SET/CIP2A, motivating both “reactivation” and selective inhibition strategies. (sarais2025targetingpp2ain pages 1-3, peris2023regulationandrole pages 10-11)

5. Current applications and real-world implementations

5.1 Clinical trials targeting PP2A catalytic activity (LB-100; inhibitor strategy)

Several ongoing/completed clinical trials use LB-100, a PP2A inhibitor, reflecting translational interest in PP2A modulation:

  • Recurrent glioblastoma / recurrent glioma (NCT03027388): Phase II, completed, n=7 actual enrollment; LB-100 given 2.33 mg/m² IV 2–4 h pre-surgery, with primary emphasis on tumor pharmacokinetics (presence/absence of drug in tumor) and PD phosphoprotein changes. (NCT03027388 chunk 1, NCT03027388 chunk 2)
  • Extensive-stage small cell lung cancer (untreated) (NCT04560972): Phase Ib, active not recruiting, n=3; LB-100 combined with carboplatin/etoposide/atezolizumab; primary endpoint is RP2D defined by DLT in cycle 1. (NCT04560972 chunk 1)
  • Metastatic microsatellite-stable colorectal cancer (NCT06012734): Phase Ib, recruiting, target n=37; LB-100 (days 1 and 3) + atezolizumab 1200 mg (day 1) in 21-day cycles; includes PD biomarkers such as serine/threonine hyperphosphorylation in WBCs and tumor drug concentrations. (NCT06012734 chunk 1, NCT06012734 chunk 2)

These studies are not PPP2CB-selective (they target PP2A more broadly), but they demonstrate real-world targeting of the PP2A catalytic machinery to reshape phosphorylation states in tumors—directly relevant to the translational landscape of PPP2CB as a catalytic subunit. (NCT04560972 chunk 1, NCT06012734 chunk 1)

5.2 PP2A reactivation strategies (SET/CIP2A/PME-1 axis)

A 2023 PP2A-B56 cancer review describes clinically motivated “reactivation” approaches, including FTY720 (fingolimod) binding SET to indirectly reactivate PP2A, while noting cardiotoxicity limits and motivating development of analogs (e.g., CM-1231) and other SET-targeting agents (e.g., OSU-2S, OP449). (peris2023regulationandrole pages 10-11)

6. Expert opinions and analysis (authoritative synthesis)

Across recent authoritative reviews, a consistent expert-level interpretation emerges:

  1. PPP2CB is best annotated as a catalytic engine whose biological meaning is determined by holoenzyme assembly—particularly which B subunit is engaged, where that holoenzyme localizes, and how it is regulated by methylation/phosphorylation and assembly chaperones. (nasa2020effectsofcarboxylterminal pages 1-3, peris2023regulationandrole pages 1-2)
  2. C-terminal methylation (Leu309) is a high-leverage control point that reshapes the cellular repertoire of PP2A complexes; this is emphasized both in biochemical reviews and in cancer-focused synthesis, and supported by quantitative methylation stoichiometry measurements in cell models. (nasa2020effectsofcarboxylterminal pages 1-3, peris2023regulationandrole pages 2-4)
  3. Disordered regions and allostery are now recognized as major regulatory modalities for PP2A holoenzymes (e.g., B56δ arms), expanding the “subunit composition only” model into a broader framework that includes conformational gating. (wu2024b56δlongdisorderedarms pages 1-2)

7. Relevant statistics and data (recent studies)

Key quantitative results are compiled in the artifacts below.

Topic Statement / Mechanism Key Quantitative Details Key Sources Citation ID
Identity UniProt P62714 corresponds to the human PP2A catalytic subunit beta isoform (PPP2CB). Encoded by PPP2CB gene; ~97% sequence identity to alpha isoform (PPP2CA). Cohen 2010 ArXiv DOI; Goguet-Rubio 2020 Biomolecules DOI (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 5-6)
Holoenzyme Composition Heterotrimeric complex: Scaffold (A) + Catalytic (C) + Regulatory (B) subunit. Combinatorial assembly of 2 C, 2 A, and ~15 B genes yields >70–90 distinct holoenzymes. Nasa 2020 Biochem Soc Trans DOI; Cohen 2010 (nasa2020effectsofcarboxylterminal pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 7-8)
Catalytic Mechanism Bimetallic (M1/M2) center activates water (bridging hydroxide) for nucleophilic attack on phosphorus. Arg89 stabilizes transition state. Activation barrier: +15.5 kcal/mol (bidentate Arg89) vs +18.8 kcal/mol (sequestered). Salter 2023 Front Cell Dev Biol DOI; Kokot 2022 J Cell Sci DOI (salter2023quantumbasedmodelingimplies pages 1-2, salter2023quantumbasedmodelingimplies pages 2-3, kokot2022emerginginsightsinto pages 1-2)
Regulation (Methylation) Reversible methylation of C-terminal Leu309 controls B-subunit binding; catalyzed by LCMT1, removed by PME1. >90% methylation in NIH3T3 cells; ~74% in transformed HEK cells. Nasa 2020 Biochem Soc Trans DOI; Goguet-Rubio 2020 (nasa2020effectsofcarboxylterminal pages 1-3, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)
Biogenesis Factors PTPA activates latent phosphatase activity (tyrosyl to seryl/threonyl) and enables methylation; alpha4 protects monomeric C. PTPA is required for proper active site metal geometry (Mg2+/Mn2+). Goguet-Rubio 2020 Biomolecules; Cohen 2010 (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 8-9)
Substrate Selection Dictated by B-subunits. B55 targets basic-rich motifs and SLiMs; B56 shows distinct basophilic preferences. B55α binds SLiM [RK]Vxx[VI]R via acidic surface; dephosphorylates >300 substrates (e.g., p53, c-MYC). Kokot 2022 J Cell Sci; Sarais 2025 J Exp Clin Cancer Res DOI (kokot2022emerginginsightsinto pages 6-7, sarais2025targetingpp2ain pages 1-3)
Disease Association PPP2CB identified as a plasma protein associated with celiac disease pathological grading. Selected by machine learning as 1 of 4 key features (AUC ~0.57 in one cohort). Li 2024 Sci Rep DOI (li2024proteomicanalysisof pages 6-8, li2024proteomicanalysisof pages 1-2)

Table: Summary of evidence-backed facts regarding the identity, enzymatic mechanism, regulation, and functional roles of the PPP2CB-encoded beta isoform of PP2A.

Item Metric Value Context/notes Source (author year) URL Citation ID
PP2A–B56 cancer review Fraction of cellular Ser/Thr phosphatase activity 50–70% >80 distinct heterotrimeric PP2A holoenzymes described Peris 2023 https://doi.org/10.1016/j.bbcan.2023.188953 (peris2023regulationandrole pages 1-2)
LCMT1 methylation stoichiometry PP2A-C Leu309 methylation >90% (NIH3T3); ~74% (transformed HEK) Methylation by LCMT1; demethylation by PME1; acts on AC dimer to bias B-subunit binding Nasa 2020 https://doi.org/10.1042/bst20200177 (nasa2020effectsofcarboxylterminal pages 1-3)
B56δ cryo-EM interface Autoinhibitory interface length >190 Å B56δ disordered arms contact holoenzyme core; allosteric network; Jordan’s syndrome mutations Wu 2024 https://doi.org/10.1073/pnas.2310727120 (wu2024b56δlongdisorderedarms pages 1-2)
PP2A catalytic mechanism Activation barrier with Arg89 vs sequestered 15.5 vs 18.8 kcal/mol Bidentate Arg89–phosphate binding lowers barrier in QM models Salter 2023 https://doi.org/10.3389/fcell.2023.1141804 (salter2023quantumbasedmodelingimplies pages 1-2)
PPP2CA substrate mapping Proteins with increased phosphorylation after PPP2CA degradation 2,204 proteins dTAG PPP2CA in HEK293; pSP/pTP motif enrichment Brewer 2024 https://doi.org/10.1016/j.isci.2024.109302 (brewer2024mappingthesubstrate pages 1-2)
Celiac disease cohorts Sample sizes (CeD vs controls) 85 CeD, 94 controls Discovery: 30 CeD plasma/19 mucosa (matched controls); Validation: 40 CeD plasma, 45 controls Li 2024 https://doi.org/10.1038/s41598-024-80391-5 (li2024proteomicanalysisof pages 9-10)
PPP2CB AUC in CeD ROC AUC for PPP2CB 0.5661 (95% CI 0.4225–0.7097), P>0.05 PPP2CB among 4 ML-selected plasma features associated with Marsh grading Li 2024 https://doi.org/10.1038/s41598-024-80391-5 (li2024proteomicanalysisof pages 6-8)
LB-100 in recurrent glioblastoma (NCT03027388) Phase/status/enrollment Phase II; Completed; n=7 LB-100 2.33 mg/m^2 IV 2–4 h pre-surgery; PK/PD endpoints ClinicalTrials.gov 2019 https://clinicaltrials.gov/study/NCT03027388 (NCT03027388 chunk 1, NCT03027388 chunk 2)
LB-100 + chemo + atezolizumab in ES-SCLC (NCT04560972) Phase/status/enrollment Phase Ib; Active, not recruiting; n=3 LB-100 IV 15 min days 1 & 3; 21-day cycles with carboplatin/etoposide/atezolizumab; RP2D/DLT primary ClinicalTrials.gov 2021 https://clinicaltrials.gov/study/NCT04560972 (NCT04560972 chunk 1)
LB-100 + atezolizumab in MSS mCRC (NCT06012734) Phase/status/enrollment Phase Ib; Recruiting; target n=37 LB-100 days 1 & 3; atezolizumab 1200 mg day 1; 21-day cycles; PD hyperphosphorylation biomarker ClinicalTrials.gov 2024 https://clinicaltrials.gov/study/NCT06012734 (NCT06012734 chunk 1, NCT06012734 chunk 2)

Table: This table compiles recent quantitative findings and implementations relevant to PPP2CB/PP2A, including structural metrics, enzymatic barriers, substrate-mapping counts, cohort sizes and AUCs, and details from active/complete clinical trials targeting PP2A. It provides traceable values and contexts to support functional annotation and translational relevance.

8. Limitations and gaps (important for functional annotation quality)

  • PPP2CB-specific substrates: most substrate-landscape studies and quantitative degradomics currently emphasize PPP2CA, not PPP2CB (e.g., 2024 dTAG-PPP2CA study). Thus, PPP2CB-specific substrate lists remain sparse in the retrieved evidence, and functional annotation for PPP2CB should primarily rely on PP2A holoenzyme biology and isoform localization/expression differences. (brewer2024mappingthesubstrate pages 1-2, baskaran2018proteinphosphatase2a pages 6-10)
  • EC number and reaction statement: While the provided UniProt entry lists EC 3.1.3.16, the retrieved literature excerpts primarily describe PP2A as a Ser/Thr phosphatase and detail its catalytic mechanism, rather than explicitly restating the EC number. (cohen2010phosphatasefamiliesdephosphorylating pages 8-9, salter2023quantumbasedmodelingimplies pages 1-2)

9. Concluding functional annotation (evidence-based)

PPP2CB (PP2Acβ; UniProt P62714) is a metal-dependent serine/threonine phosphoprotein phosphatase catalytic subunit that functions predominantly as part of heterotrimeric PP2A holoenzymes (A scaffold + C catalytic + B regulatory). Its effective substrate specificity and localization are governed by regulatory B subunits and by catalytic-tail post-translational regulation (notably Leu309 methylation via LCMT1/PME-1 and nearby phosphorylation). PPP2CB is described as being predominantly cytoplasmic and nuclear, consistent with roles in cytoplasmic/nuclear dephosphorylation networks in contexts where it is expressed and assembled into active PP2A complexes. Recent 2023–2024 research has sharpened mechanistic understanding via (i) a modern specificity framework (motifs + SLiMs), (ii) structural/allosteric models of B56 holoenzyme autoinhibition and disease-mutation coupling, and (iii) emerging biomarker signals in disease proteomics where PPP2CB appears as a machine-learning–selected plasma feature (currently hypothesis-generating). (baskaran2018proteinphosphatase2a pages 6-10, nasa2020effectsofcarboxylterminal pages 1-3, wu2024b56δlongdisorderedarms pages 1-2, nguyen2023substrateandphosphorylation pages 1-3, li2024proteomicanalysisof pages 6-8)

References

  1. (cohen2010phosphatasefamiliesdephosphorylating pages 5-6): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.

  2. (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3): Perrine Goguet-Rubio, Priya Amin, Sushil Awal, Suzanne Vigneron, Sophie Charrasse, Francisca Mechali, Jean Claude Labbé, Thierry Lorca, and Anna Castro. Pp2a-b55 holoenzyme regulation and cancer. Biomolecules, 10:1586, Nov 2020. URL: https://doi.org/10.3390/biom10111586, doi:10.3390/biom10111586. This article has 27 citations.

  3. (cohen2010phosphatasefamiliesdephosphorylating pages 8-9): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.

  4. (kokot2022emerginginsightsinto pages 1-2): Thomas Kokot and Maja Köhn. Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity. Journal of cell science, Oct 2022. URL: https://doi.org/10.1242/jcs.259618, doi:10.1242/jcs.259618. This article has 33 citations and is from a domain leading peer-reviewed journal.

  5. (nasa2020effectsofcarboxylterminal pages 1-3): Isha Nasa and Arminja N. Kettenbach. Effects of carboxyl-terminal methylation on holoenzyme function of the pp2a subfamily. Biochemical Society transactions, 48 5:2015-2027, Oct 2020. URL: https://doi.org/10.1042/bst20200177, doi:10.1042/bst20200177. This article has 22 citations and is from a peer-reviewed journal.

  6. (peris2023regulationandrole pages 1-2): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.

  7. (cohen2010phosphatasefamiliesdephosphorylating pages 7-8): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.

  8. (salter2023quantumbasedmodelingimplies pages 1-2): E. Alan Salter, Andrzej Wierzbicki, Richard E. Honkanen, and Mark R. Swingle. Quantum-based modeling implies that bidentate arg89-substrate binding enhances serine/threonine protein phosphatase-2a(ppp2r5d/ppp2r1a/ppp2ca)-mediated dephosphorylation. Frontiers in Cell and Developmental Biology, Jun 2023. URL: https://doi.org/10.3389/fcell.2023.1141804, doi:10.3389/fcell.2023.1141804. This article has 3 citations.

  9. (kokot2022emerginginsightsinto pages 6-7): Thomas Kokot and Maja Köhn. Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity. Journal of cell science, Oct 2022. URL: https://doi.org/10.1242/jcs.259618, doi:10.1242/jcs.259618. This article has 33 citations and is from a domain leading peer-reviewed journal.

  10. (nguyen2023substrateandphosphorylation pages 3-4): Hieu Nguyen and Arminja N. Kettenbach. Substrate and phosphorylation site selection by phosphoprotein phosphatases. Trends in Biochemical Sciences, 48:713-725, Aug 2023. URL: https://doi.org/10.1016/j.tibs.2023.04.004, doi:10.1016/j.tibs.2023.04.004. This article has 42 citations and is from a domain leading peer-reviewed journal.

  11. (verbinnen2021proteinphosphatase2a pages 1-5): Iris Verbinnen, Pieter Vaneynde, Sara Reynhout, Lisa Lenaerts, Rita Derua, Gunnar Houge, and Veerle Janssens. Protein phosphatase 2a (pp2a) mutations in brain function, development, and neurologic disease. Biochemical Society transactions, 49:1567-1588, Jul 2021. URL: https://doi.org/10.1042/bst20201313, doi:10.1042/bst20201313. This article has 53 citations and is from a peer-reviewed journal.

  12. (baskaran2018proteinphosphatase2a pages 6-10): Rathinasamy Baskaran and Bharath Kumar Velmurugan. Protein phosphatase 2a as therapeutic targets in various disease models. Life Sciences, 210:40–46, Oct 2018. URL: https://doi.org/10.1016/j.lfs.2018.08.063, doi:10.1016/j.lfs.2018.08.063. This article has 79 citations and is from a peer-reviewed journal.

  13. (peris2023regulationandrole pages 2-4): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.

  14. (wu2024b56δlongdisorderedarms pages 1-2): Cheng-Guo Wu, Vijaya K. Balakrishnan, Ronald A. Merrill, Pankaj S. Parihar, Kirill Konovolov, Yu-Chia Chen, Zhen Xu, Hui Wei, Ramya Sundaresan, Qiang Cui, Brian E. Wadzinski, Mark R. Swingle, Alla Musiyenko, Wendy K. Chung, Richard E. Honkanen, Aussie Suzuki, Xuhui Huang, Stefan Strack, and Yongna Xing. B56δ long-disordered arms form a dynamic pp2a regulation interface coupled with global allostery and jordan’s syndrome mutations. Proceedings of the National Academy of Sciences of the United States of America, Dec 2024. URL: https://doi.org/10.1073/pnas.2310727120, doi:10.1073/pnas.2310727120. This article has 22 citations and is from a highest quality peer-reviewed journal.

  15. (nguyen2023substrateandphosphorylation pages 1-3): Hieu Nguyen and Arminja N. Kettenbach. Substrate and phosphorylation site selection by phosphoprotein phosphatases. Trends in Biochemical Sciences, 48:713-725, Aug 2023. URL: https://doi.org/10.1016/j.tibs.2023.04.004, doi:10.1016/j.tibs.2023.04.004. This article has 42 citations and is from a domain leading peer-reviewed journal.

  16. (li2024proteomicanalysisof pages 6-8): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.

  17. (li2024proteomicanalysisof pages 9-10): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.

  18. (sarais2025targetingpp2ain pages 1-3): Fabio Sarais, Finja Krempien, Caroline Koehn, Lara Brewing, Carl Friedrich Classen, Michael Walter, and Olia Shokraie. Targeting pp2a in cancer: an underrated option. Journal of Experimental & Clinical Cancer Research, Oct 2025. URL: https://doi.org/10.1186/s13046-025-03560-y, doi:10.1186/s13046-025-03560-y. This article has 1 citations and is from a domain leading peer-reviewed journal.

  19. (peris2023regulationandrole pages 10-11): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.

  20. (NCT03027388 chunk 1): Eric Burton. Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03027388

  21. (NCT03027388 chunk 2): Eric Burton. Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03027388

  22. (NCT04560972 chunk 1): LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer. City of Hope Medical Center. 2021. ClinicalTrials.gov Identifier: NCT04560972

  23. (NCT06012734 chunk 1): LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients. The Netherlands Cancer Institute. 2024. ClinicalTrials.gov Identifier: NCT06012734

  24. (NCT06012734 chunk 2): LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients. The Netherlands Cancer Institute. 2024. ClinicalTrials.gov Identifier: NCT06012734

  25. (salter2023quantumbasedmodelingimplies pages 2-3): E. Alan Salter, Andrzej Wierzbicki, Richard E. Honkanen, and Mark R. Swingle. Quantum-based modeling implies that bidentate arg89-substrate binding enhances serine/threonine protein phosphatase-2a(ppp2r5d/ppp2r1a/ppp2ca)-mediated dephosphorylation. Frontiers in Cell and Developmental Biology, Jun 2023. URL: https://doi.org/10.3389/fcell.2023.1141804, doi:10.3389/fcell.2023.1141804. This article has 3 citations.

  26. (li2024proteomicanalysisof pages 1-2): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.

  27. (brewer2024mappingthesubstrate pages 1-2): Abigail Brewer, Gajanan Sathe, Billie E. Pflug, Thomas J. Macartney, and Gopal P. Sapkota. Mapping the substrate landscape of protein phosphatase 2a catalytic subunit ppp2ca. iScience, Sep 2024. URL: https://doi.org/10.1016/j.isci.2024.109302, doi:10.1016/j.isci.2024.109302. This article has 17 citations and is from a peer-reviewed journal.

Citations

  1. cohen2010phosphatasefamiliesdephosphorylating pages 5-6
  2. salter2023quantumbasedmodelingimplies pages 1-2
  3. nguyen2023substrateandphosphorylation pages 3-4
  4. peris2023regulationandrole pages 2-4
  5. nguyen2023substrateandphosphorylation pages 1-3
  6. li2024proteomicanalysisof pages 6-8
  7. peris2023regulationandrole pages 10-11
  8. peris2023regulationandrole pages 1-2
  9. nasa2020effectsofcarboxylterminal pages 1-3
  10. brewer2024mappingthesubstrate pages 1-2
  11. li2024proteomicanalysisof pages 9-10
  12. cohen2010phosphatasefamiliesdephosphorylating pages 8-9
  13. kokot2022emerginginsightsinto pages 1-2
  14. cohen2010phosphatasefamiliesdephosphorylating pages 7-8
  15. kokot2022emerginginsightsinto pages 6-7
  16. salter2023quantumbasedmodelingimplies pages 2-3
  17. li2024proteomicanalysisof pages 1-2
  18. DOI
  19. RK
  20. VI
  21. https://doi.org/10.1016/b978-0-12-374145-5.00085-1
  22. https://doi.org/10.3390/biom10111586
  23. https://doi.org/10.1042/bst20200177
  24. https://doi.org/10.3389/fcell.2023.1141804
  25. https://doi.org/10.1242/jcs.259618
  26. https://doi.org/10.1186/s13046-025-03560-y
  27. https://doi.org/10.1038/s41598-024-80391-5
  28. https://doi.org/10.1016/j.bbcan.2023.188953
  29. https://doi.org/10.1073/pnas.2310727120
  30. https://doi.org/10.1016/j.isci.2024.109302
  31. https://clinicaltrials.gov/study/NCT03027388
  32. https://clinicaltrials.gov/study/NCT04560972
  33. https://clinicaltrials.gov/study/NCT06012734
  34. https://doi.org/10.1016/b978-0-12-374145-5.00085-1,
  35. https://doi.org/10.3390/biom10111586,
  36. https://doi.org/10.1242/jcs.259618,
  37. https://doi.org/10.1042/bst20200177,
  38. https://doi.org/10.1016/j.bbcan.2023.188953,
  39. https://doi.org/10.3389/fcell.2023.1141804,
  40. https://doi.org/10.1016/j.tibs.2023.04.004,
  41. https://doi.org/10.1042/bst20201313,
  42. https://doi.org/10.1016/j.lfs.2018.08.063,
  43. https://doi.org/10.1073/pnas.2310727120,
  44. https://doi.org/10.1038/s41598-024-80391-5,
  45. https://doi.org/10.1186/s13046-025-03560-y,
  46. https://doi.org/10.1016/j.isci.2024.109302,

📚 Additional Documentation

Notes

(PPP2CB-notes.md)

PPP2CB Review Notes

Gene Identity

PPP2CB (UniProt P62714) encodes the catalytic subunit beta isoform of protein phosphatase 2A (PP2A-beta, PP2Acbeta). It is the minor catalytic isoform of PP2A, with PPP2CA being the major isoform (~10x more abundant in most tissues). The two share ~97% sequence identity [deep-research-falcon, goguetrubio2020, "~97% sequence similarity/identity reported in multiple authoritative reviews"].

Core Function

PPP2CB is a metal-dependent serine/threonine phosphoprotein phosphatase (EC 3.1.3.16). It uses a bimetallic Mn2+ active site to hydrolyze phospho-serine and phospho-threonine bonds on protein substrates [PMID:10318862, deep-research-falcon].

The protein functions as the catalytic subunit of the heterotrimeric PP2A holoenzyme complex, consisting of:
- A (scaffold) subunit (PPP2R1A or PPP2R1B)
- C (catalytic) subunit (PPP2CA or PPP2CB)
- B (regulatory) subunit (multiple families: B/B55, B'/B56, B'', B''')

Regulatory B subunits determine substrate specificity and subcellular localization. Combinatorial assembly yields >70-90 distinct PP2A holoenzymes [deep-research-falcon, nasa2020].

Regulation

  • C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1/PPME1) controls B subunit selection [PMID:8206937, "carboxyl-methylated in vivo...Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide"]
  • PTPA activates latent phosphatase; alpha4 (IGBP1) protects monomeric C subunit [PMID:9647778, "alpha 4 associates constitutively with the catalytic subunits of PP4, PP6, and both isoforms of PP2A"]

Subcellular Localization

PPP2CB is predominantly cytoplasmic and nuclear [deep-research-falcon, baskaran2018, "Cbeta (PPP2CB) is predominantly cytoplasmic and nuclear"]. During prometaphase, localizes to centromeres; during mitosis, found at spindle poles [UniProt subcellular location, PMID:16541025].

STRIPAK Complex

PPP2CB is part of the STRIPAK complex [PMID:18782753, "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2...PDCD10...and members of the germinal center kinase III family of Ste20 kinases"].

Key Protein Interactions (from GOA IPI annotations)

  • AXIN2 (Q9Y2T1) - via PMID:10698523 - PP2A complexed with Axin dephosphorylates APC in Wnt signaling
  • TIPRL (O75663) - via PMID:16085932 and PMID:27880917 - PP complex regulator
  • IGBP1/alpha4 (P78318) - via PMID:9647778, PMID:18782753, PMID:19156129, PMID:26496610, PMID:27880917, PMID:33961781, PMID:35271311 - protects monomeric PP2A C subunit
  • STRIP1 (Q5VSL9) - via PMID:18782753, PMID:25531779, PMID:26496610, PMID:28514442, PMID:33961781, PMID:35271311 - STRIPAK component
  • FHL1B (Q13642-2) - via PMID:20969868 - LIM domain protein, cell cycle
  • TTP/ZFP36 (P26651) - via PMID:21784977 - mRNA stability regulator
  • FMR1 (Q06787-7) - via PMID:32814053 - FMRP, neurodegenerative interactome

NF-kappaB and Inflammatory Signaling

PMID:28159925 shows PPP2CB knockdown in MSCs increases RELA/p65 levels and, in combination with TNFalpha, enhances IL-6, CCL2, and CCL5 transcription. PPP2CB is a direct target of miR-1246. This supports roles in negative regulation of NF-kappaB and TNF-mediated signaling, but the effects are context-dependent (require TNFalpha co-stimulation for pro-inflammatory cytokine changes).

Tau and Neurodegeneration

PP2A is the major tau phosphatase in human brain, accounting for ~71% of tau phosphatase activity PMID:16262633. PP2A activity negatively correlates with tau phosphorylation. This supports annotations related to tau binding and neurofibrillary tangle regulation, though these studies used PP2A broadly (not PPP2CB-specific).

Key Considerations for Annotation Review

  1. Many "protein binding" IPI annotations are from HTP interactome studies - these are uninformative per se, but reflect real PP2A subunit interactions and complex membership
  2. IEA annotations transferred from rat PPP2CB (P62716) are generally appropriate given near-100% sequence identity
  3. Response to lead ion annotation is based on ISS from rat - indirect evidence
  4. Several Reactome cytosol annotations all relate to SPRY2 regulation of FGF signaling pathway

📄 View Raw YAML

id: P62714
gene_symbol: PPP2CB
product_type: PROTEIN
status: IN_PROGRESS
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  PPP2CB encodes the beta isoform of the catalytic subunit of protein phosphatase
  2A (PP2A), a major serine/threonine phosphatase (EC 3.1.3.16). PP2Acbeta is the
  minor catalytic isoform (~97% identical to the alpha isoform PPP2CA, which is ~10x
  more abundant). The catalytic subunit uses a bimetallic Mn2+ active site to
  dephosphorylate phosphoserine and phosphothreonine residues on protein substrates.
  PP2A functions as a heterotrimeric holoenzyme consisting of a scaffold A subunit,
  catalytic C subunit, and one of many regulatory B subunits that confer substrate
  specificity and subcellular localization. Combinatorial assembly of subunit
  isoforms generates >70 distinct PP2A holoenzymes. PP2Acbeta is predominantly
  cytoplasmic and nuclear, and is also a component of the STRIPAK complex.
  C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) is a key regulatory
  mechanism controlling B subunit selection and holoenzyme assembly. PP2A opposes
  kinase signaling in numerous pathways including cell cycle, Wnt/beta-catenin,
  Ras/MAPK, NF-kappaB, and PI3K/Akt, and is a major regulator of tau
  phosphorylation in brain.
existing_annotations:
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      PPP2CB is a well-established serine/threonine phosphoprotein phosphatase.
      This is the core molecular function of the protein, supported by extensive
      biochemical evidence and phylogenetic analysis across eukaryotes. The IBA
      annotation is well supported by broad phylogenetic conservation.
    action: ACCEPT
    reason: >-
      This is the defining molecular function of PPP2CB. The protein catalyzes
      dephosphorylation of phosphoserine and phosphothreonine residues using a
      bimetallic active site. Supported by UniProt EC 3.1.3.16 assignment, deep
      research review, and phylogenetic inference.
    supported_by:
    - reference_id: PMID:8206937
      supporting_text: "Methylation of PP2Ac subunit, in vitro, increases its activity
        toward both phosphorylase a and a phosphopeptide."
    - reference_id: PMID:2849765
      supporting_text: "The nucleotide sequence of the cDNA encoding the human lung
        protein phosphatase 2A beta catalytic subunit."
- term:
    id: GO:0000278
    label: mitotic cell cycle
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      PP2A holoenzymes (with B55 and B56 regulatory subunits) play essential
      roles in mitotic cell cycle regulation, opposing CDK-mediated
      phosphorylation during cell cycle transitions. The IBA annotation is
      phylogenetically well-supported.
    action: ACCEPT
    reason: >-
      PP2A is a central regulator of mitotic cell cycle progression. PP2A-B55
      and PP2A-B56 are required for mitotic exit, opposing CDK substrates.
      UniProt lists roles in kinetochore/centromere and spindle pole
      localization during mitosis. The phylogenetic inference is appropriate.
    supported_by:
    - reference_id: PMID:27880917
      supporting_text: "complementary affinity purification and proximity-based interaction
        proteomics approaches to generate a physical interactome for 140 human proteins
        harboring phosphatase catalytic domains"
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      PPP2CB is active in the cytosol, consistent with its role as a major
      cytoplasmic phosphatase. The IBA annotation is well supported by both
      phylogenetic evidence and experimental localization data.
    action: ACCEPT
    reason: >-
      Cytosolic localization of PP2A catalytic subunits is well established.
      UniProt lists cytoplasm as a subcellular location for PPP2CB. Reactome
      pathways also place PPP2CB in cytosol for various signaling events.
    supported_by:
    - reference_id: PMID:16541025
      supporting_text: "PP2A colocalizes with shugoshin at centromeres and is required
        for centromeric protection."
- term:
    id: GO:0000775
    label: chromosome, centromeric region
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      IEA annotation derived from UniProt subcellular location vocabulary.
      UniProt cites PMID:16541025 (Kitajima et al. 2006) showing PP2A localizes
      to centromeres in prometaphase cells via interaction with SGO1.
    action: ACCEPT
    reason: >-
      The localization is experimentally supported. UniProt states:
      "In prometaphase cells, but not in anaphase cells, localizes at
      centromeres." This is based on PMID:16541025 which directly demonstrated
      PP2A-SGO1 interaction at centromeres.
    supported_by:
    - reference_id: PMID:16541025
      supporting_text: "a specific subtype of serine/threonine protein phosphatase
        2A (PP2A) associating with human shugoshin. PP2A colocalizes with shugoshin
        at centromeres"
- term:
    id: GO:0000922
    label: spindle pole
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      IEA from UniProt subcellular location. UniProt states PP2A is found at
      spindle poles during mitosis, based on PMID:16541025.
    action: ACCEPT
    reason: >-
      Spindle pole localization during mitosis is documented in UniProt
      subcellular location, which cites PMID:16541025. Consistent with PP2A
      role in mitotic regulation.
    supported_by:
    - reference_id: PMID:16541025
      supporting_text: "crucial--particularly at centromeres--for proper chromosome
        segregation in mitosis and meiosis"
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      Combined automated annotation from multiple IEA methods confirming
      protein serine/threonine phosphatase activity. Redundant with IBA and
      TAS annotations for the same term but independently valid.
    action: ACCEPT
    reason: >-
      Correct core function. This IEA annotation is consistent with the more
      authoritative IBA and TAS annotations for the same GO term.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      IEA from UniProt subcellular location. PPP2CB has been experimentally
      shown to localize to the nucleus, consistent with its role in nuclear
      phosphatase activity and its description as predominantly cytoplasmic
      and nuclear.
    action: ACCEPT
    reason: >-
      Nuclear localization is well supported. UniProt cites PMID:16541025 and
      also states PPP2CB is nucleoplasmic (IDA from HPA). Deep research
      confirms PPP2CB is predominantly cytoplasmic and nuclear.
    supported_by:
    - reference_id: PMID:16541025
      supporting_text: "PP2A colocalizes with shugoshin at centromeres and is required
        for centromeric protection"
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      IEA annotation for cytoplasm localization. Broader than cytosol but still
      correct. PPP2CB is well established as a cytoplasmic protein.
    action: ACCEPT
    reason: >-
      Cytoplasm is a broader parent term of cytosol. PPP2CB is well established
      in both cytosol and cytoplasm. Consistent with IBA cytosol annotation and
      UniProt subcellular location.
- term:
    id: GO:0016787
    label: hydrolase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: >-
      IEA from InterPro domain mapping. Hydrolase activity is correct but too
      general for a protein whose specific phosphatase activity is well
      characterized. The more specific GO:0004722 annotations exist.
    action: ACCEPT
    reason: >-
      While very broad, hydrolase activity is technically correct as a parent
      of phosphatase activity. The more specific GO:0004722 annotations also
      exist. This IEA is acceptable as a domain-based annotation even though
      more informative terms are present.
- term:
    id: GO:0090443
    label: FAR/SIN/STRIPAK complex
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: >-
      IEA from ARBA machine learning model predicting STRIPAK complex
      membership. This is consistent with experimental evidence from
      PMID:18782753 (IDA annotation also present).
    action: ACCEPT
    reason: >-
      Correct annotation. PPP2CB was experimentally identified as part of the
      STRIPAK complex in PMID:18782753, and a separate IDA annotation exists.
      This IEA is redundant but valid.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:10698523
  review:
    summary: >-
      IPI based on interaction with AXIN2 (Q9Y2T1). The study showed PP2A
      complexed with Axin dephosphorylates APC in Wnt signaling. The
      interaction is functionally meaningful (Wnt pathway regulation) but
      annotated as generic protein binding.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The interaction with AXIN2 reflects
      PP2A recruitment to the beta-catenin destruction complex. A more
      informative annotation would capture the specific functional context
      (e.g., phosphatase activity in the Wnt pathway), but that is a BP
      annotation, not MF. The IPI evidence does not support a more specific
      MF term than protein binding.
    supported_by:
    - reference_id: PMID:10698523
      supporting_text: "the heterodimeric form of protein phosphatase 2A (PP2A) directly
        bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated
        by GSK-3beta"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:16085932
  review:
    summary: >-
      IPI based on interaction with TIPRL (O75663). The study characterized a
      PP4 complex involved in cisplatin sensitivity. TIPRL is a known PP2A
      interactor and phosphatase regulator. Annotated as generic protein binding.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. TIPRL interaction with PP2A catalytic
      subunits is part of the phosphatase regulatory network, but the GO
      term does not capture the functional significance. The primary study
      focused on PP4, not PP2A.
    supported_by:
    - reference_id: PMID:16085932
      supporting_text: "Using a combination of tandem affinity purification tagging
        and mass spectrometry, we characterized a novel, evolutionarily conserved
        protein phosphatase 4 (PP4)-containing complex"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:18782753
  review:
    summary: >-
      IPI for interaction with IGBP1/alpha4 (P78318) and STRIP1 (Q5VSL9) from
      the PP2A high-density interaction network study that defined the STRIPAK
      complex. These are well-established PP2A complex components.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. Both IGBP1 and STRIP1 are functional
      PP2A-associated proteins. The interactions are better captured by the
      STRIPAK complex (GO:0090443) and PP2A complex (GO:0000159) annotations.
    supported_by:
    - reference_id: PMID:18782753
      supporting_text: "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding
        (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated
        protein Mob3, the novel proteins STRIP1 and STRIP2"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:19156129
  review:
    summary: >-
      IPI for interaction with IGBP1 (P78318) from an integrated PP2A
      interaction proteomics workflow. This is a well-characterized PP2A
      regulatory interaction.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. IGBP1/alpha4 is a known PP2A
      chaperone/regulatory protein. Better captured by complex membership
      annotations.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20969868
  review:
    summary: >-
      IPI for interaction with FHL1B (Q13642-2). Study demonstrated FHL1B
      specifically interacts with PP2A catalytic beta subunit (PPP2CB) by
      yeast two-hybrid and co-immunoprecipitation, suggesting a novel
      cell-cycle regulatory pathway.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The FHL1B interaction is PPP2CB-specific
      (not shown for PPP2CA) and linked to cell cycle regulation, which is
      interesting but the GO term does not capture this specificity.
    supported_by:
    - reference_id: PMID:20969868
      supporting_text: "FHL1B was demonstrated to interact with the beta catalytic
        subunit (Cbeta) of a type 2A protein phosphatase (PP2A) by yeast two-hybrid
        screening"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:25531779
  review:
    summary: >-
      IPI for interaction with STRIP1 (Q5VSL9) from STRIPAK complex study on
      cancer cell migration and metastasis. High-throughput proteomics study.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. STRIP1 interaction is part of STRIPAK
      complex, better captured by GO:0090443.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:26496610
  review:
    summary: >-
      IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from
      quantitative human interactome study. Large-scale proteomics.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. Both are known PP2A complex components.
      High-throughput study; interactions better captured by complex annotations.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:27880917
  review:
    summary: >-
      IPI for interactions with TIPRL (O75663) and IGBP1 (P78318) from
      comprehensive phosphatase interactome profiling. Study identified
      diverse mitotic regulators among phosphatase interactors.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. Both TIPRL and IGBP1 are established
      PP2A regulators. The study provides valuable interactome data but
      protein binding does not convey functional information.
    supported_by:
    - reference_id: PMID:27880917
      supporting_text: "complementary affinity purification and proximity-based interaction
        proteomics approaches to generate a physical interactome for 140 human proteins
        harboring phosphatase catalytic domains"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:28514442
  review:
    summary: >-
      IPI for interaction with STRIP1 (Q5VSL9) from architecture of the human
      interactome study. Large-scale proteomics.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. STRIP1 is a STRIPAK component.
      High-throughput study.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32814053
  review:
    summary: >-
      IPI for interaction with FMR1/FMRP (Q06787-7) from neurodegenerative
      disease interactome mapping study. The interaction was identified by
      mass spectrometry in a large-scale screen.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The FMR1 interaction is from a
      high-throughput screen and the functional significance for PPP2CB is
      unclear. PP2A may dephosphorylate FMRP but this is not demonstrated
      in this study.
    supported_by:
    - reference_id: PMID:32814053
      supporting_text: "Interactome Mapping Provides a Network of Neurodegenerative
        Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains"
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:33961781
  review:
    summary: >-
      IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from dual
      proteome-scale cell-specific interactome study.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. Both are established PP2A complex
      members. High-throughput study.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:35271311
  review:
    summary: >-
      IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from the
      OpenCell endogenous tagging study. Large-scale proteomics.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. Both are known PP2A/STRIPAK complex
      members. High-throughput study.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:9647778
  review:
    summary: >-
      IPI for interaction with IGBP1/alpha4 (P78318). Study demonstrated
      alpha4 associates constitutively with both PP2A catalytic isoforms,
      PP4C, and PP6C. This is a well-established functional interaction
      where alpha4 serves as a chaperone protecting monomeric PP2A C subunit.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The alpha4-PP2Ac interaction is
      functionally important for PP2A biogenesis and stability. However,
      the GO term protein binding does not capture this functional role.
    supported_by:
    - reference_id: PMID:9647778
      supporting_text: "alpha 4, a previously identified phosphoprotein, associates
        constitutively with the catalytic subunits of PP4, PP6, and both isoforms
        of PP2A"
- term:
    id: GO:0000159
    label: protein phosphatase type 2A complex
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA from Ensembl Compara transfer from mouse PPP2CB. PPP2CB is a
      catalytic subunit of the PP2A holoenzyme complex, which is its primary
      functional context.
    action: ACCEPT
    reason: >-
      Core annotation. PPP2CB is a defining component of the PP2A
      holoenzyme complex. Strongly supported by extensive biochemical and
      structural evidence. Also has a TAS annotation (PMID:8206937).
- term:
    id: GO:0004721
    label: phosphoprotein phosphatase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA from Ensembl Compara. Phosphoprotein phosphatase activity is a
      parent term of protein serine/threonine phosphatase activity
      (GO:0004722). Correct but less specific than GO:0004722.
    action: ACCEPT
    reason: >-
      Technically correct as PPP2CB does have phosphoprotein phosphatase
      activity. More specific GO:0004722 annotations are also present. This
      broader IEA is acceptable.
- term:
    id: GO:0010288
    label: response to lead ion
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA transferred from rat PPP2CB (P62716) via Ensembl Compara. Based on
      rat studies showing PP2A activity is affected by lead exposure. Duplicate
      with ISS annotation below.
    action: KEEP_AS_NON_CORE
    reason: >-
      Response to lead ion is not a core function of PPP2CB. Lead ions can
      inhibit PP2A activity (as they affect many metalloenzymes), but this is
      a toxicological response rather than a primary biological function.
      Keeping as non-core given the supporting evidence from rat studies.
- term:
    id: GO:0031113
    label: regulation of microtubule polymerization
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA transferred from rat PPP2CB via Ensembl Compara. PP2A regulates
      microtubule dynamics through dephosphorylation of MAPs (MAP1b, MAP2, tau).
      This is consistent with PP2A's role in cytoskeletal regulation.
    action: KEEP_AS_NON_CORE
    reason: >-
      PP2A regulates microtubule polymerization indirectly by dephosphorylating
      microtubule-associated proteins. PMID:10640627 showed PP2A regulates
      MAP1b and MAP2 phosphorylation and their microtubule binding activity.
      This is a downstream consequence of PP2A phosphatase activity rather
      than a core function of PPP2CB specifically.
    supported_by:
    - reference_id: PMID:10640627
      supporting_text: "The inhibition of PP2A, and to a lesser extent of PP2B, was
        found to induce an increased phosphorylation of MAP1b and inhibit its microtubule
        binding activity"
- term:
    id: GO:0044325
    label: transmembrane transporter binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA transferred from rat PPP2CB via Ensembl Compara. PP2A interacts
      with various membrane transporters and channels to regulate their
      phosphorylation state. Limited direct evidence for PPP2CB specifically.
    action: UNDECIDED
    reason: >-
      The evidence for transmembrane transporter binding is based on
      computational transfer from rat. While PP2A can regulate transporter
      phosphorylation, the specificity and directness of a binding interaction
      is not well documented for PPP2CB specifically. Unable to verify the
      original rat experimental evidence.
- term:
    id: GO:0046580
    label: negative regulation of Ras protein signal transduction
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      IEA transferred from rat PPP2CB via Ensembl Compara. PP2A
      dephosphorylates components of the Ras/MAPK pathway, acting as a
      negative regulator. This is well established for PP2A holoenzymes
      generally.
    action: KEEP_AS_NON_CORE
    reason: >-
      PP2A is well established as a negative regulator of Ras/MAPK signaling,
      including dephosphorylation of RAF and ERK pathway components. However,
      this represents one of many PP2A-regulated pathways and is driven by
      specific B subunit combinations rather than PPP2CB specifically. Deep
      research review confirms PP2A antagonizes Ras/MAPK signaling.
- term:
    id: GO:0005654
    label: nucleoplasm
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: >-
      IDA from HPA immunofluorescence data. PPP2CB was detected in
      nucleoplasm by immunofluorescence. Consistent with UniProt subcellular
      location annotation showing nuclear localization.
    action: ACCEPT
    reason: >-
      Nucleoplasm localization is experimentally supported by HPA
      immunofluorescence and consistent with UniProt subcellular location
      showing nuclear localization (PMID:16541025). Deep research also
      describes PPP2CB as predominantly cytoplasmic and nuclear.
- term:
    id: GO:1902996
    label: regulation of neurofibrillary tangle assembly
  evidence_type: TAS
  original_reference_id: PMID:16262633
  review:
    summary: >-
      TAS annotation based on a study showing PP2A is the major tau
      phosphatase in human brain (~71% of total tau phosphatase activity),
      and PP2A activity is decreased in AD brain, correlating with tau
      hyperphosphorylation and neurofibrillary tangle formation.
    action: KEEP_AS_NON_CORE
    reason: >-
      While PP2A is clearly the major tau phosphatase, this represents a
      downstream physiological consequence of PP2A phosphatase activity in
      brain rather than a core function of PPP2CB. Additionally, the study
      used PP2A generally (likely predominantly PPP2CA given its higher
      expression in brain). The annotation is not wrong but represents a
      non-core, tissue-specific function.
    supported_by:
    - reference_id: PMID:16262633
      supporting_text: "PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately
        11%, approximately 10% and approximately 7%, respectively, of the total tau
        phosphatase activity of human brain"
- term:
    id: GO:0043124
    label: negative regulation of canonical NF-kappaB signal transduction
  evidence_type: IGI
  original_reference_id: PMID:28159925
  review:
    summary: >-
      IGI annotation from a study showing miR-1246 directly targets PPP2CB,
      and PPP2CB knockdown increases p65/NF-kappaB levels in MSCs. The IGI
      evidence is based on interaction with RELA/p65 (Q04206).
    action: KEEP_AS_NON_CORE
    reason: >-
      The study provides evidence that PPP2CB negatively regulates NF-kappaB
      signaling, but in a specific cellular context (MSCs in tumor
      microenvironment). PPP2CB knockdown increased RELA expression and total
      p65 levels but did not directly increase phospho-p65. The effect on
      pro-inflammatory cytokines required additional TNFalpha stimulation.
      This represents a non-core, context-dependent function.
    supported_by:
    - reference_id: PMID:28159925
      supporting_text: "Knock-down of PPP2CB significantly increased RELA expression"
    - reference_id: PMID:28159925
      supporting_text: "knock-down of either PRKAR1A or PPP2CB led to a significant
        up-regulation of total p65 in MSCs whereas phosphorylation of p65 at Ser536
        remained unaffected"
- term:
    id: GO:0090443
    label: FAR/SIN/STRIPAK complex
  evidence_type: IDA
  original_reference_id: PMID:18782753
  review:
    summary: >-
      IDA annotation showing PPP2CB is part of the STRIPAK complex, based
      on iterative affinity purification/mass spectrometry in human cells.
      The study defined the STRIPAK complex and identified PPP2CB as a core
      component.
    action: ACCEPT
    reason: >-
      Well-supported experimental evidence. The study used iterative AP-MS
      to identify PPP2CB in the STRIPAK complex, which contains PP2A
      catalytic and scaffolding subunits, striatins, MOB4, STRIP1/2, PDCD10,
      and STE20 kinases. This is a core complex for PPP2CB function.
    supported_by:
    - reference_id: PMID:18782753
      supporting_text: "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding
        (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated
        protein Mob3, the novel proteins STRIP1 and STRIP2"
- term:
    id: GO:0010629
    label: negative regulation of gene expression
  evidence_type: IGI
  original_reference_id: PMID:28159925
  review:
    summary: >-
      IGI annotation (with TNFalpha P01375) showing PPP2CB acts upstream of
      negative regulation of gene expression. Based on the miR-1246/PPP2CB
      study in MSCs where PPP2CB knockdown combined with TNFalpha enhanced
      expression of pro-inflammatory genes.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      This annotation is overly broad. The study showed PPP2CB knockdown
      combined with TNFalpha increases IL-6, CCL2, CCL5 transcription in
      MSCs. This means PPP2CB normally negatively regulates expression of
      these specific inflammatory genes, but the term "negative regulation
      of gene expression" is too generic. Additionally, the qualifier is
      acts_upstream_of rather than involved_in, indicating indirect effects.
    supported_by:
    - reference_id: PMID:28159925
      supporting_text: "knock-down of PPP2CB in combination with TNFalpha stimulation
        phenocopied the miR-1246-enhanced transcriptional response of IL-6"
- term:
    id: GO:0010629
    label: negative regulation of gene expression
  evidence_type: IMP
  original_reference_id: PMID:28159925
  review:
    summary: >-
      IMP annotation showing PPP2CB is involved in negative regulation of
      gene expression, based on the same miR-1246 study in MSCs.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Same concern as the IGI annotation above. The term is too broad. The
      evidence shows PPP2CB normally suppresses inflammatory gene expression
      in MSCs, but this is a very general biological process annotation that
      does not capture specificity. The NF-kappaB annotation (GO:0043124)
      is more specific and informative.
    supported_by:
    - reference_id: PMID:28159925
      supporting_text: "knock-down of PPP2CB significantly decreased releases of IL-6
        and CCL2"
- term:
    id: GO:0010804
    label: negative regulation of tumor necrosis factor-mediated signaling
      pathway
  evidence_type: IGI
  original_reference_id: PMID:28159925
  review:
    summary: >-
      IGI annotation showing PPP2CB acts upstream of negative regulation of
      TNF-mediated signaling. Based on the miR-1246 study where PPP2CB
      knockdown combined with TNFalpha enhances inflammatory responses.
    action: KEEP_AS_NON_CORE
    reason: >-
      The evidence supports that PPP2CB negatively regulates TNF-mediated
      signaling in MSCs. PPP2CB knockdown released negative feedback on
      IL-6 transcription after TNFalpha stimulation. However, this is a
      context-dependent effect in MSCs and represents a non-core function.
    supported_by:
    - reference_id: PMID:28159925
      supporting_text: "knock-down of PPP2CB in combination with TNFalpha stimulation
        phenocopied the miR-1246-enhanced transcriptional response of IL-6 in combination
        with TNFalpha"
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: TAS
  original_reference_id: PMID:8206937
  review:
    summary: >-
      TAS annotation from the study that demonstrated carboxyl methylation of
      PP2A catalytic subunit in vivo. The paper confirms PP2Ac phosphatase
      activity toward phosphorylase a and phosphopeptide substrates.
    action: ACCEPT
    reason: >-
      Core molecular function, directly supported by the cited publication
      which demonstrated PP2Ac enzymatic activity.
    supported_by:
    - reference_id: PMID:8206937
      supporting_text: "Methylation of PP2Ac subunit, in vitro, increases its activity
        toward both phosphorylase a and a phosphopeptide"
- term:
    id: GO:0048156
    label: tau protein binding
  evidence_type: NAS
  original_reference_id: PMID:28386764
  review:
    summary: >-
      NAS annotation based on a comprehensive review of tau protein roles in
      health and disease. PP2A is well established as the major tau
      phosphatase, which implies physical binding to tau.
    action: KEEP_AS_NON_CORE
    reason: >-
      PP2A does bind and dephosphorylate tau protein, but this is primarily
      documented for PP2A holoenzymes in brain (likely predominantly
      PPP2CA-containing). The NAS evidence from a review article is weak.
      Tau binding is a substrate interaction for PP2A rather than a core
      binding function. Keeping as non-core given that PP2A-tau interaction
      is well established in the broader literature.
    supported_by:
    - reference_id: PMID:28386764
      supporting_text: "Tau is well established as a microtubule-associated protein
        in neurons"
    - reference_id: PMID:16262633
      supporting_text: "PP2A is the major tau phosphatase that regulates its phosphorylation
        at multiple sites in human brain"
- term:
    id: GO:0010288
    label: response to lead ion
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS annotation transferred from rat PPP2CB (P62716) by curator
      judgment. PP2A activity can be affected by lead exposure, as lead
      interferes with the metalloenzyme's active site.
    action: KEEP_AS_NON_CORE
    reason: >-
      Consistent with the IEA annotation for the same term. Response to lead
      ion is a toxicological response rather than a core function. The ISS
      transfer from rat is appropriate given near-identical sequence.
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS annotation transferred from rat PPP2CB (P62716). Core phosphatase
      activity, redundant with other annotations for the same term.
    action: ACCEPT
    reason: >-
      Correct core function. ISS transfer from rat is fully appropriate
      given near-100% sequence identity between human and rat PPP2CB.
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: TAS
  original_reference_id: PMID:10640627
  review:
    summary: >-
      TAS annotation from a study on PP2A regulation of MAP1b and MAP2
      phosphorylation in rat brain. Confirms PP2A serine/threonine
      phosphatase activity toward neuronal substrates.
    action: ACCEPT
    reason: >-
      Core molecular function. The study directly demonstrated PP2A
      phosphatase activity toward MAP substrates.
    supported_by:
    - reference_id: PMID:10640627
      supporting_text: "PP2A might be the major PP that participates in regulation
        of the phosphorylation of MAP1b and MAP2 and their biological activities"
- term:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  evidence_type: TAS
  original_reference_id: PMID:16262633
  review:
    summary: >-
      TAS annotation from the tau phosphorylation study. PP2A accounts for
      ~71% of tau phosphatase activity in human brain.
    action: ACCEPT
    reason: >-
      Core molecular function. The study quantitatively demonstrated PP2A
      phosphatase activity toward tau.
    supported_by:
    - reference_id: PMID:16262633
      supporting_text: "PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately
        11%, approximately 10% and approximately 7%, respectively, of the total tau
        phosphatase activity of human brain"
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1295599
  review:
    summary: >-
      TAS from Reactome pathway for SPRY2 translocation to plasma membrane.
      Places PPP2CB in cytosol as part of Spry regulation of FGF signaling.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct and well-supported. Reactome annotation
      reflects PPP2CB involvement in SPRY2/FGF signaling regulation in the
      cytosol.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1295609
  review:
    summary: >-
      TAS from Reactome pathway for SRC phosphorylation of SPRY2. Places
      PPP2CB in cytosol.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct. Redundant with other cytosol
      annotations but valid from Reactome evidence.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1295613
  review:
    summary: >-
      TAS from Reactome pathway for SPRY2-GRB2 binding. Places PPP2CB in
      cytosol.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct. Redundant with other cytosol
      annotations but valid.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1295622
  review:
    summary: >-
      TAS from Reactome pathway for SPRY2-CBL binding. Places PPP2CB in
      cytosol.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct. Redundant with other cytosol
      annotations but valid.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1295632
  review:
    summary: >-
      TAS from Reactome pathway for PP2A dephosphorylation of SPRY2. This
      directly reflects PP2A phosphatase activity in the cytosol acting on
      the SPRY2 substrate.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct and directly relevant to PP2A function.
      This Reactome entry describes the actual dephosphorylation reaction
      catalyzed by PP2A on SPRY2.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1549564
  review:
    summary: >-
      TAS from Reactome pathway for PTPN11 dephosphorylation of SPRY2.
      Places PPP2CB in cytosol.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct. Redundant with other cytosol
      annotations.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-934559
  review:
    summary: >-
      TAS from Reactome pathway for SPRY2 phosphorylation by MNK1. Places
      PPP2CB in cytosol.
    action: ACCEPT
    reason: >-
      Cytosol localization is correct. Redundant with other cytosol
      annotations.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:21784977
  review:
    summary: >-
      IPI for interaction with TTP/ZFP36 (P26651). The study focused on TTP
      regulation of CCL3 mRNA and tissue inflammation. The interaction with
      PPP2CB was likely identified as part of a broader interactome screen.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The TTP-PPP2CB interaction may
      reflect PP2A regulation of TTP phosphorylation (TTP activity is
      regulated by phosphorylation), but the study focused on TTP-mRNA
      interactions, not PP2A function.
    supported_by:
    - reference_id: PMID:21784977
      supporting_text: "Zinc finger protein tristetraprolin (TTP) modulates macrophage
        inflammatory activity by destabilizing cytokine mRNAs"
- term:
    id: GO:0000159
    label: protein phosphatase type 2A complex
  evidence_type: TAS
  original_reference_id: PMID:8206937
  review:
    summary: >-
      TAS annotation from the carboxyl-methylation study, which demonstrated
      PP2A exists as a complex with methylated catalytic subunit. The study
      worked with PP2A holoenzyme from MCF7 cells.
    action: ACCEPT
    reason: >-
      Core annotation. PPP2CB is a defining component of the PP2A complex.
      The study directly worked with PP2A holoenzyme complexes.
    supported_by:
    - reference_id: PMID:8206937
      supporting_text: "Treatment of extracts from human breast cancer (MCF7) cells
        with either alkali or ethanol increased immunoreactivity of PP2Ac subunit
        severalfold"
- term:
    id: GO:0006470
    label: protein dephosphorylation
  evidence_type: TAS
  original_reference_id: PMID:2849765
  review:
    summary: >-
      TAS annotation from the original cDNA cloning paper for human PPP2CB.
      The paper established PPP2CB as a phosphatase catalytic subunit.
    action: ACCEPT
    reason: >-
      Core biological process. Protein dephosphorylation is the fundamental
      reaction catalyzed by PPP2CB. This is directly supported by the
      identification of PPP2CB as a PP2A catalytic subunit.
    supported_by:
    - reference_id: PMID:2849765
      supporting_text: "The nucleotide sequence of the cDNA encoding the human lung
        protein phosphatase 2A beta catalytic subunit"
- term:
    id: GO:0046872
    label: metal ion binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      PPP2CB requires two Mn2+ ions at its active site for catalytic
      activity. Metal ion binding is inherent to its phosphatase mechanism.
      This annotation is present in UniProt GO lines but was not in the
      GOA TSV extract; adding as it appears in UniProt.
    action: NEW
    reason: >-
      PPP2CB uses a bimetallic Mn2+ active site for catalysis. UniProt lists
      multiple Mn2+ binding sites (residues 57, 59, 85, 117, 167, 241) and
      includes metal ion binding as a GO annotation. This is a core aspect
      of the catalytic mechanism.
    supported_by:
    - reference_id: PMID:10318862
      supporting_text: "substitution of glutamine for either of two putative active
        site histidines in the PP2A C subunit results in inactivation of PP2A"
core_functions:
- molecular_function:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  description: >-
    PPP2CB is the beta catalytic subunit of PP2A, a major cellular Ser/Thr phosphatase
    (EC 3.1.3.16). It dephosphorylates phosphoserine and phosphothreonine residues
    on
    protein substrates using a bimetallic Mn2+ active site. PPP2CB functions as the
    catalytic engine of heterotrimeric PP2A holoenzymes (A scaffold + C catalytic
    + B
    regulatory subunit). Substrate specificity is determined by the regulatory B subunit
    incorporated into the holoenzyme. PPP2CB is the minor catalytic isoform (~97%
    identical to PPP2CA but ~10x less abundant), and is predominantly cytoplasmic
    and
    nuclear. C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) regulates
    holoenzyme assembly and B subunit selection.
  directly_involved_in:
  - id: GO:0006470
    label: protein dephosphorylation
  - id: GO:0000278
    label: mitotic cell cycle
  locations:
  - id: GO:0005829
    label: cytosol
  - id: GO:0005654
    label: nucleoplasm
  in_complex:
    id: GO:0000159
    label: protein phosphatase type 2A complex
  supported_by:
  - reference_id: PMID:8206937
    supporting_text: >-
      Methylation of PP2Ac subunit, in vitro, increases its activity toward both
      phosphorylase a and a phosphopeptide.
  - reference_id: PMID:2849765
    supporting_text: >-
      The nucleotide sequence of the cDNA encoding the human lung protein phosphatase
      2A beta catalytic subunit.
  - reference_id: PMID:16262633
    supporting_text: >-
      PP2A accounted for approximately 71% of the total tau phosphatase activity of
      human brain.
    full_text_unavailable: true
- molecular_function:
    id: GO:0004722
    label: protein serine/threonine phosphatase activity
  description: >-
    PPP2CB functions as the catalytic subunit within the STRIPAK complex
    (FAR/SIN/STRIPAK complex), a large signaling assembly that includes PP2A catalytic
    and scaffolding subunits, striatins (B''' regulatory subunits), MOB4, STRIP1/2,
    PDCD10/CCM3, and germinal center kinase III family STE20 kinases. In this context,
    PPP2CB provides phosphatase activity that opposes the kinase activities within
    the
    complex, regulating cell migration, polarity, and cerebral cavernous malformation
    signaling.
  directly_involved_in:
  - id: GO:0006470
    label: protein dephosphorylation
  locations:
  - id: GO:0005829
    label: cytosol
  in_complex:
    id: GO:0090443
    label: FAR/SIN/STRIPAK complex
  supported_by:
  - reference_id: PMID:18782753
    supporting_text: >-
      STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits,
      the striatins (PP2A regulatory B''' subunits), the striatin-associated protein
      Mob3, the novel proteins STRIP1 and STRIP2, PDCD10, and members of the germinal
      center kinase III family of Ste20 kinases.
    full_text_unavailable: true
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with
    GO terms
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to
    orthologs by curator judgment of sequence similarity
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping,
    accompanied by conservative changes to GO terms applied by UniProt
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular
    Location vocabulary mapping, accompanied by conservative changes to GO terms
    applied by UniProt
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data
    to orthologs using Ensembl Compara
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning
    models
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
  findings: []
- id: PMID:2849765
  title: The nucleotide sequence of the cDNA encoding the human lung protein
    phosphatase 2A beta catalytic subunit.
  findings:
  - statement: Original cDNA cloning and sequencing of human PPP2CB from lung
      tissue.
- id: PMID:8206937
  title: The catalytic subunit of protein phosphatase 2A is carboxyl-methylated
    in vivo.
  findings:
  - statement: Demonstrated carboxyl-methylation of PP2Ac at Leu-309 in vivo;
      methylation increases phosphatase activity.
- id: PMID:9647778
  title: Alpha 4 associates with protein phosphatases 2A, 4, and 6.
  findings:
  - statement: Alpha4/IGBP1 constitutively associates with PP2A, PP4, and PP6
      catalytic subunits.
- id: PMID:10318862
  title: A protein phosphatase methylesterase (PME-1) is one of several novel
    proteins stably associating with two inactive mutants of protein phosphatase
    2A.
  findings:
  - statement: Identified PME-1 as PP2A demethylase; H59Q and H118Q mutations
      inactivate PP2A catalytic activity.
- id: PMID:10640627
  title: Regulation of phosphorylation of neuronal microtubule-associated
    proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain.
  findings:
  - statement: PP2A is the major phosphatase regulating MAP1b and MAP2
      phosphorylation and microtubule binding activity.
- id: PMID:10698523
  title: GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene
    product can be modulated by beta-catenin and protein phosphatase 2A
    complexed with Axin.
  findings:
  - statement: PP2A directly binds Axin and dephosphorylates APC phosphorylated
      by GSK-3beta in Wnt signaling.
- id: PMID:16085932
  title: A novel, evolutionarily conserved protein phosphatase complex involved
    in cisplatin sensitivity.
  findings:
  - statement: Characterized PP4-containing complex; TIPRL interacts with PP2A
      family catalytic subunits.
- id: PMID:16262633
  title: Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the
    regulation of tau phosphorylation.
  findings:
  - statement: PP2A accounts for ~71% of total tau phosphatase activity in human
      brain; activity decreased in AD brain.
- id: PMID:16541025
  title: Shugoshin collaborates with protein phosphatase 2A to protect cohesin.
  findings:
  - statement: PP2A localizes to centromeres in prometaphase via SGO1
      interaction; also found at spindle poles during mitosis.
- id: PMID:18782753
  title: A PP2A phosphatase high density interaction network identifies a novel
    striatin-interacting phosphatase and kinase complex linked to the cerebral
    cavernous malformation 3 (CCM3) protein.
  findings:
  - statement: Defined the STRIPAK complex containing PP2A catalytic/scaffolding
      subunits, striatins, MOB4, STRIP1/2, PDCD10, and STE20 kinases.
- id: PMID:19156129
  title: 'An integrated workflow for charting the human interaction proteome: insights
    into the PP2A system.'
  findings:
  - statement: Mapped the PP2A interaction network including IGBP1/alpha4
      binding to PP2A catalytic subunits.
- id: PMID:20969868
  title: "LIM domain protein FHL1B interacts with PP2A catalytic β subunit--a novel
    cell cycle regulatory pathway."
  findings:
  - statement: FHL1B specifically interacts with PPP2CB (not PPP2CA was tested)
      by yeast two-hybrid and co-IP; linked to cell cycle regulation.
- id: PMID:21784977
  title: Zinc finger protein tristetraprolin interacts with CCL3 mRNA and
    regulates tissue inflammation.
  findings:
  - statement: TTP/ZFP36 interacts with PPP2CB; TTP modulates inflammatory
      cytokine mRNA stability.
- id: PMID:25531779
  title: STRIPAK components determine mode of cancer cell migration and
    metastasis.
  findings:
  - statement: STRIPAK complex components including STRIP1 interact with PP2A
      catalytic subunits in cancer cell migration.
- id: PMID:26496610
  title: A human interactome in three quantitative dimensions organized by
    stoichiometries and abundances.
  findings:
  - statement: High-throughput interactome study confirming IGBP1 and STRIP1
      interactions with PPP2CB.
- id: PMID:27880917
  title: Phenotypic and Interaction Profiling of the Human Phosphatases
    Identifies Diverse Mitotic Regulators.
  findings:
  - statement: Comprehensive phosphatase interactome profiling; PPP2CB interacts
      with TIPRL and IGBP1.
- id: PMID:28159925
  title: miRNA-1246 induces pro-inflammatory responses in mesenchymal
    stem/stromal cells by regulating PKA and PP2A.
  findings:
  - statement: PPP2CB is a direct target of miR-1246; knockdown increases
      p65/NF-kappaB and enhances TNF-mediated inflammatory gene expression in
      MSCs.
- id: PMID:28386764
  title: Roles of tau protein in health and disease.
  findings:
  - statement: Review describing PP2A as a major tau phosphatase, with relevance
      to tauopathies.
- id: PMID:28514442
  title: Architecture of the human interactome defines protein communities and
    disease networks.
  findings:
  - statement: Large-scale interactome study confirming STRIP1 interaction with
      PPP2CB.
- id: PMID:32814053
  title: Interactome Mapping Provides a Network of Neurodegenerative Disease
    Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
  findings:
  - statement: Identified PPP2CB-FMR1 interaction in neurodegenerative disease
      protein network.
- id: PMID:33961781
  title: Dual proteome-scale networks reveal cell-specific remodeling of the
    human interactome.
  findings:
  - statement: Cell-specific interactome confirming IGBP1 and STRIP1
      interactions with PPP2CB.
- id: PMID:35271311
  title: 'OpenCell: Endogenous tagging for the cartography of human cellular organization.'
  findings:
  - statement: Endogenous tagging proteomics confirming IGBP1 and STRIP1
      interactions with PPP2CB.
- id: Reactome:R-HSA-1295599
  title: SPRY2 translocates to the plasma membrane
  findings: []
- id: Reactome:R-HSA-1295609
  title: SRC phosphorylates SPRY2 on Y55 and Y227
  findings: []
- id: Reactome:R-HSA-1295613
  title: SPRY2 binds GRB2
  findings: []
- id: Reactome:R-HSA-1295622
  title: SPRY2 binds CBL
  findings: []
- id: Reactome:R-HSA-1295632
  title: PPA2A dephosphorylates SPRY2
  findings: []
- id: Reactome:R-HSA-1549564
  title: PPTN11 dephosphorylates SPRY2
  findings: []
- id: Reactome:R-HSA-934559
  title: SPRY2 is phosphorylated by phosphorylated MNK1
  findings: []